US Pat. No. 10,457,967

IN-SITU BIOSTIMULATION OF THE HYDROLYSIS OF ORGANIC MATTER FOR OPTIMIZING THE ENERGY RECOVERY THEREFROM

1. A process for the treatment of a first, at least partially organic and at least partially solid, substrate, comprising:A. introduction of an initial volume of said first substrate to be treated into at least one hydrolysis reactor;
B. introduction of an initial volume of second substrate into at least one biostimulation reactor;
C. biostimulation of the second substrate contained in said biostimulation reactor by indigenous microorganisms and absent inoculated exogenous strains, under aerobic conditions, at a temperature of between 20° C. and 40° C., a pH of between 4 and 7, a moisture level of between 50% and 80% and a residence time of between 1 and 5 days, to ensure at least partial hydrolysis of the organic portion of said substrate and the in situ production of hydrolytic enzymes;
D. percolation of a liquid through said volume of second substrate contained in said biostimulation reactor, in order to form a first leachate enriched in hydrolytic enzymes;
E. injection of the first leachate enriched in hydrolytic enzymes into at least one hydrolysis reactor containing said first substrate to be treated; and
F. hydrolysis of the first substrate at least partially by the first enriched leachate; wherein the succession of the steps C and D define a biostimulation cycle.
US Pat. No. 10,458,993

ASSAY FOR ASSESSING CONFORMATIONAL STABILITY OF MEMBRANE PROTEIN

Heptares Therapeutics Lim...

1. An assay for assessing the conformational stability of a membrane protein, comprising:(a) providing a sample comprising a first population and a second population of a membrane protein; wherein the membrane protein in the first population is labelled with a donor label and the membrane protein in the second population is labelled with an acceptor label, or the membrane protein in the first population is labelled with an acceptor label and the membrane protein in the second population is labelled with a donor label, and wherein the populations of membrane protein are provided in a solubilized form,
(b) exposing the first and second populations of the membrane protein provided in the solubilized form to a denaturant or denaturing condition, and
(c) assessing aggregation between membrane proteins of the first and second populations by activating the donor label to permit a distance-dependent interaction with the acceptor label, which interaction produces a detectable signal.
US Pat. No. 10,456,429

USE OF PROBIOTIC MICRO-ORGANISMS AS AN AGENT THAT PROMOTES THE SYNTHESIS OF MELANIN

NESTEC S.A., Vevey (CH)

1. A non-therapeutic cosmetic method which comprises topically administering to a subject at least one probiotic Bifidobacterium longum subsp. longum micro-organism strain registered on Jan. 29, 2001 with CNCM (Paris, France) under the number I-2618, as an agent inducing skin and/or hair pigmentation, for promoting melanin synthesis thereby homogenizing the color of the skin and/or hair of said subject, wherein said Bifidobacterium longum subsp. longum CNCM I-2618 strain is in at least partially inactivated form and is presented in the form of a cell extract or lysate containing cell fragments and metabolites.
US Pat. No. 10,457,712

PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. An expression vector expressing a nucleic acid encoding a peptide consisting of the amino acid sequence of GLIDEVMVL (SEQ ID NO: 22) or FLDANGHFV (SEQ ID NO: 23).
US Pat. No. 10,457,968

MODIFIED TYPE A DNA POLYMERASES

Kapa Biosystems, Inc., W...

1. A modified Taq DNA polymerase that:(i) has an amino acid sequence that has at least 95% amino acid sequence identity with wild type Taq DNA polymerase set out in SEQ ID NO.:1, but includes a substitution relative to SEQ ID NO: 1 at a position corresponding to position 507 of SEQ ID NO.:1, which substitution is E507K; and
(ii) has polymerase activity in catalyzing DNA template-directed synthesis of a DNA polynucleotide, which activity has increased salt-tolerance relative to the wild type Taq DNA polymerase of SEQ ID NO.:1.
US Pat. No. 10,457,713

GLYCOPROTEIN HORMONE LONG-ACTING SUPERAGONISTS

TROPHOGEN, INC., Rockvil...

1. A modified human follicle stimulating hormone (FSH) wherein the ? subunit (SEQ ID NO: 13) comprises arginine, histidine, or lysine substitutions at at least one of T11, Q13, E14, P16, and Q20, and an insert of NVTINVT (SEQ ID NO: 46) between V4 and Q5.
US Pat. No. 10,457,969

POLYNUCLEOTIDE ENRICHMENT USING CRISPR-CAS SYSTEMS

Illumina, Inc., San Dieg...

1. A method for enriching a target nucleic acid from a population of cell free DNAs (cfDNAs) comprising:obtaining a population of cfDNAs from a subject's plasma or serum, the population of cfDNAs containing the target nucleic acid;
providing an endonuclease system having:
a clustered regularly interspaced short palindromic repeats (CRISPR) RNA (crRNA), and
a CRISPR-associated (Cas) protein,
wherein the crRNA contains a target-specific nucleotide region complementary to a region of the target nucleic acid;
contacting the target nucleic acid with the endonuclease system to form a complex,
wherein the crRNA in the complex formed by the endonuclease system is labeled with a binding tag; and
separating the complex from the population of cfDNAs using the binding tag, thereby enriching for the target nucleic acid.
US Pat. No. 10,456,431

TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION

Vedanta Biosciences, Inc....

1. A pharmaceutical composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO:20, and SEQ ID NO:21; and one or more enteric polymers; wherein the pharmaceutical composition comprises between 1×107 and 1×1010 colony forming units (CFUs) per bacterial strain; and wherein the pharmaceutical composition is in the form of a capsule.
US Pat. No. 10,457,714

ACYLATED GLUCAGON ANALOGUES


wherein:
X2 is selected from Aib, Ala, D-Ala, Ser, N-Me-Ser, Ac3c, Ac4c and Ac5c; and
X3 is selected from Gln and His;
P2 is absent or is a sequence of 1-20 amino acid units independently selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn;
or a pharmaceutically acceptable salt thereof; and
? is a residue of Lys, Arg, Orn or Cys in which the side chain is conjugated to a substituent having the formula —Z2—Z1;
—Z1 is a fatty chain having a polar group at one end of the chain and connected via a bond to Z2 at the end of the chain distal from the polar group, and
wherein —Z1 is selected from carboxyphenoxynonanoyl, 13-carboxy-tridecanoyl, 15-carboxy-pentadecanoyl and 17-carboxy-heptadecanoyl-; and
—Z2— is a spacer selected from:
isoGlu, isoGlu-Peg3-Peg3, isoGlu-Peg4-Peg4, Peg3-Peg3-isoGlu, isoGlu-Gly-Ser-Gly-Ser-Gly-Gly (isoGlu-GSGSGG), and Ala-Ala-Peg3-Peg3 (AA-Peg3-Peg3);
or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,457,970

EXPRESSION OF MODIFIED GLYCOPROTEINS AND GLYCOPEPTIDES

Conagen Inc., Bedford, M...

1. A recombinant cell of the Class Labyrinthulomycetes comprising a genetic modification of a gene that encodes a mannosyl transferase, and further comprising a recombinant nucleic acid encoding a functional glycoprotein or glycopeptide, wherein the cell produces a heterologous glycoprotein or glycopeptide having an N-linked glycan profile that has at least 25% fewer high mannose structures than the N-linked glycan profile from a reference cell that does not comprise the genetic modification in the gene that encodes the mannosyl transferase.
US Pat. No. 10,458,996

METHODS FOR DETERMINING CLINICAL RESPONSE TO TNF-ALPHA AND/OR JAK INHIBITORS IN SUBJECTS WITH INFLAMMATORY DISEASES

Beth Israel Deaconess Med...

1. A method of determining the number of cytokines, chemokines and inflammatory mediators exhibiting statistically significant down-regulation after contacting a candidate compound with a mucosal explant culture of a biopsy from a macroscopically diseased area of an inflamed intestinal mucosa from a subject having inflammatory bowel disease (IBD), the method comprising:(a) comparing the expression levels of a panel of cytokines, chemokines, and inflammatory mediators relating to IBD or treatment thereof, in the supernatant of a first mucosal explant culture and in the supernatant of a second mucosal explant culture; and,
(b) determining the number of cytokines, chemokines and inflammatory mediators, from said panel of cytokines, chemokines, and inflammatory mediators, that exhibit statistically significant down-regulation in the second mucosal explant culture compared to the first mucosal explant culture;wherein said first mucosal explant culture is produced from the biopsy in the absence of a candidate compound, and said second mucosal explant culture is produced from the biopsy in the presence of the candidate compound; and,wherein said panel comprises, consists essentially of, or consists of: interleukin 17A (IL-17A), interleukin 7 (IL-7), interleukin 5 (IL-5), interleukin 4 (IL-4), interleukin 13 (IL-13), granulocyte macrophage colony-stimulating factor (GM-CSF), interferon gamma (IFN?), interleukin 10 (IL-10), interleukin 12 70-kDa (IL-12p70), interleukin 12 40-kDa (IL-12p40), interleukin 1 beta (IL-1?), interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor alpha (TNF?), optionally further comprising, consisting essentially of, or consisting of one or more of: interleukin 3 (IL-3), interleukin 9 (IL-9), interleukin 22 (IL-22), interleukin 23 (IL-23), interleukin 25 (IL-25), interleukin 35 (IL-35), interleukin 36 (IL-36), interleukin 37 (IL-37), TNF-like ligand 1A (TL1A), LIGHT (Lymphotoxin-like Inducible protein that competes with Glycoprotein D for Herpesvirus entry on T cells) and Transforming Growth Factor-beta (TGF-beta).
US Pat. No. 10,456,432

ONCOLYTIC HERPES SIMPLEX VIRUS AND THERAPEUTIC USES THEREOF

New York University, New...

1. A variant oncolytic herpes simplex virus (HSV) comprising functionally inactive ICP34.5 encoding genes, wherein at least one of the ICP34.5 encoding genes is rendered functionally inactive by the insertion of an expression cassette comprising:(a) a US11 encoding polynucleotide operably associated with an immediate early (IE) promoter;
(b) a virus-derived heterologous transporter associated with antigen presentation (TAP) inhibitor encoding polynucleotide; and
(c) a CD40 ligand encoding polynucleotide.
US Pat. No. 10,457,715

OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL

President and Fellows of ...

1. A polynucleotide encoding a polypeptide having at least 80% identity to SEQ ID NO: 1, wherein the polypeptide comprises, relative to SEQ ID NO: 1, at leasta first substitution mutation selected from the group consisting of D95Q and D106H; and
a second substitution mutation selected from the group consisting of P60S, T80S, and F161V.
US Pat. No. 10,456,433

SUPPRESSIVE AGENT FOR RHEUMATOID ARTHRITIS, PROPHYLACTIC AGENT FOR RHEUMATOID ARTHRITIS, THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS, AND FOOD FOR SUPPRESSING RHEUMATOID ARTHRITIS

euglena Co., Ltd., Tokyo...

1. A method of treating a human suffering from rheumatoid arthritis comprising administering a therapeutically effective amount of Euglena to said human to effectively treat the rheumatoid arthritis in said human.
US Pat. No. 10,457,716

PROTEIN FOLDING AND METHODS OF USING SAME

University of Notre Dame ...

1. A method for microscale production of a complex protein comprising at least a first protein of interest and a second protein of interest, wherein at least one protein of interest is a recombinant protein, comprising the steps of:diluting a denatured solubilized protein preparation comprising a first protein of interest to provide a diluted preparation;
dialyzing the diluted preparation at a temperature of between 4° C. and 32° C. for 1 to 3 hours to provide a first correctly folded first protein of interest preparation; and
adding a volume of a second protein of interest to the first protein of interest preparation to form a complex protein preparation comprising the complex protein;
adding the complex protein preparation to a purification reagent, the purification reagent capable of capturing the complex protein; and
obtaining the complex protein,wherein the complex protein has a biologically active folded protein structure, said method is completed in less than 24 hours,at least one protein of interest comprises ?2-microglobulin (?2m), a class I major histocompatibility complex protein heavy chain (MHC-HC), or a class I MHC binding molecule, andwherein each preparation has a final volume of less than 1 milliliter.
US Pat. No. 10,457,972

MASS SPECTROMETRIC DETERMINATION OF MICROBIAL RESISTANCES

1. A method of analyzing the resistance or susceptibility of microbes from a sample under investigation to an antibiotic, the method comprising:providing a synthetic growth medium which contains proteinogenic amino acids, wherein at least one of the amino acids is isotopically labeled, and wherein all of the isotopically labeled amino acids are labeled with isotopes from the group consisting of carbon, nitrogen, oxygen and sulfur and have the same integer mass difference ?m in relation to corresponding unlabeled amino acids;
cultivating said microbes in a first culture using the synthetic growth medium with the addition of the antibiotic;
cultivating said microbes in a second culture using the synthetic growth medium without the addition of said antibiotic; and
acquiring mass spectra of the microbes from the first and second cultures and comparing them to each other to determine an extent of a mass shift by said integer mass difference in the spectrum of the first culture.
US Pat. No. 10,456,434

EXTRACTS OBTAINED FROM CELL LINE CULTURES FROM PLANTS BELONGING TO THE OLEACEAE FAMILY (E.G. SYRINGA VULGARIS), THEIR PREPARATION AND USE

CRODA ITALIANA S. P. A., ...

1. A method of treating one of juvenile acne, diseases of the prostate, and hair loss in a human or animal subject, the method comprising:orally administering an effective amount of verbascoside and/or isoverbascoside to induce anti-lipoxygenase and/or anti-5-alpha reductase action in the subject, wherein the administered effective amount is between 0.1 mg and 2 g per day for a period of time between 1 and 120 days.
US Pat. No. 10,457,717

ENGINEERED POLYPEPTIDES

DENALI THERAPEUTICS INC.,...

1. A transferrin receptor (TfR) construct comprising from N- to C-terminus:(a) a first polypeptide comprising a C-terminal fragment of a TfR apical domain;
(b) an optional linker; and
(c) a second polypeptide comprising an N-terminal fragment of the TfR apical domain,
wherein the first polypeptide, the optional linker, and the second polypeptide are fused in a tandem series.
US Pat. No. 10,457,973

METHOD FOR RAPIDLY DETERMINING EFFECTIVE STERILIZATION, DEIMMUNIZATION, AND/OR DISINFECTION

representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device;subjecting the defined surrogate protein having the predetermined sequence to sterilization, deimmunization, or disinfection; and
determining the effectiveness of the sterilization, deimmunization, and/or disinfection by determining if the defined surrogate protein having the predetermined sequence has been destroyed, wherein the sterilization, deimmunization, and/or disinfection occurs when the defined surrogate protein has been fragmented to yield a negative result in a protein analysis procedure.
US Pat. No. 10,456,435

TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME

Christopher A. McElvany, ...

1. A stick or pen consisting essentially of a cannabinoid from cannabis, tea tree oil, beeswax, lanolin wax and cocoa butter.
US Pat. No. 10,457,718

COMPOUNDS FOR THE TREATMENT OF CANCER

Rheinisch-Westfaelische T...

1. An isolated polypeptide having a growth inhibitory effect on human cancer cells, wherein said polypeptide consists of SEQ ID NO: 2.
US Pat. No. 10,456,436

USE OF HERBAL SAPONINS TO REGULATE GUT MICROFLORA

1. A method of altering bacterial abundance of microbiota in digestive organs of a subject in need thereof, comprising administering to said subject a composition comprising saponins extracted from Gynostemma pentaphyllum at a dose of 40 mg of said saponins per kg of said subject daily.
US Pat. No. 10,457,719

ANTIBODIES AND FC FUSION PROTEIN MODIFICATIONS WITH ENHANCED PERSISTENCE OR PHARMACOKINETIC STABILITY IN VIVO AND METHODS OF USE THEREOF

The Jackson Laboratory, ...


US Pat. No. 10,457,975

HOLLOW ROTATING DEVICE FOR SEPARATING PARTICLES FROM BLOOD

1. A method for separating a particle from an original suspension of particles in a fluid, the fluid including red and white blood cells where the particle being separated is not a red or white blood cell, and has a sedimentation velocity that is slower than the sedimentation velocity of an average red blood cell, the method comprising:a. placing at least 0.5 ml of the original suspension within a cavity of a hollow device, the cavity having fluid communication with at least one partly open channel located along a side of the hollow device, the cavity of internal geometry such that when rotated a volume of the original suspension is forced into the least one partly open channel and forms a film along a back wall of the at least one partly open channel;
b. rotating the hollow device for at least a time in which a combination of rotation time and angular velocity of the hollow device allows a plurality of layers to form by sedimentation within the film, including a first layer comprising a greater red blood cell number density than the number density of red blood cells in the original suspension and a second layer comprising a red blood cell number density less than the number density of red blood cells in the original suspension;
c. slowing the spinning of the hollow device in a manner to prevent remixing of the first and second layers, the particle being separated located within the second layer; and
d. stopping the spinning of the hollow device, providing gravity driven migration of the first layer into the at least one partly open channel, which forces at least a portion of the second layer into the cavity of the hollow device for collection.
US Pat. No. 10,456,437

ANTIBACTERIAL WET WIPE FOR SKIN CARE

1. An antibacterial wet wipe for skin care, wherein the wipe is prepared by adding an antibacterial skin care additive solution to a spunlaced non-woven fabric which is used as a base material, wherein the antibacterial skin care additive solution consists of the following components by mass fraction:Tea tree essential oil 5-10%,
Nano silver 2-4%,
Neroli essential oil 3-5%,
Ceramide 1-1.5%,
Glycerin 1-3%,
Water-soluble vitamin E 0-3%,
Emulsifier 0.1-0.5%, and
Deionized water balance,
wherein the nano silver is derived from a nano silver solution with a mass percentage concentration from 500 ppm to 1000 ppm and the average particle size of the nano silver is 1-5 nm, and
wherein the emulsifier is carbomer.
US Pat. No. 10,457,720

ROBUST ANTIBODY PURIFICATION

Merck Patent GmbH, Darms...

1. A method for the separation of host cell proteins, antibody fragments and low molecular weight substances from solutions containing antibodies, said method comprising:contacting a solution containing antibodies with a hydrophobic chromatography material for a period of time whereby the antibodies stay in solution and host cell proteins, antibody fragments and low molecular weight substances are adsorbed by the hydrophobic chromatography material,
wherein said hydrophobic chromatography material is a particulate material consisting of polystyrene or poly(ethyl)styrene, which is cross-linked with copolymer of divinylbenzene and ethyleneglycol methacrylate in a ratio of 98:2 up to 10:90% by weight.
US Pat. No. 10,457,976

PREPARING ANTIBODIES FROM CHO CELL CULTURES FOR CONJUGATION

Seattle Genetics, Inc., ...

1. A method of producing a conjugated antibody, comprising:(a) performing at least one purification step of a purification scheme to obtain at least a partially purified preparation of an antibody from a culture of CHO cells expressing the antibody;
(b) testing the preparation for presence of a CHO cell sulfhydryl oxidizing enzyme;
(c) if the enzyme is detected at a level greater than 0.5 ?g/ml or 33 ppm in the preparation of step (b), repeating steps (a) and (b);
(d) if the enzyme is detected at a level less than 0.5 ?g/ml or 33 ppm in the preparation of step (b), performing the at least one purification step to obtain at least a partially purified preparation of antibody, wherein the at least one purification step of the purification scheme comprises at least one of a step of (i) washing a protein A column with a salt wash at a concentration of 150-500 mM NaCl, (ii) performing depth filtration at 230 L/m2/hr and using at least 15 L/m2 of an equilibration buffer with a pH of 7.5-8 and NaCl concentration of 50-100 mM, (iii) using anion exchange with a quaternary ammonium ion column with a buffer having a pH of 7.5-8 and a conductivity of less than or equal to 11 mS/cm, and (iv) performing phenyl membrane filtration using a buffer having a pH of 6-8 and 0.3-0.4M sodium citrate; and
(e) conjugating the at least partially purified antibody via one or more sulfhydryl groups to a cytotoxic drug to produce the conjugated antibody.
US Pat. No. 10,456,438

COMPOSITION FOR TREATING PRURITUS

1. A composition for treating itching, burning and discomfort of the skin and/or mucous membranes of the perianal and vaginal regions, the composition consisting essentially of Aloe barbadensis leaf gel, deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Hamamelis virginiana extract, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, propanediol and hydrocortisone.
US Pat. No. 10,457,721

ANTI-OSPA ANTIBODIES AND METHODS OF USE

University of Massachuset...

1. An isolated antibody that specifically binds to outer surface protein A (OspA), wherein the antibody comprises the following six CDRs:(a) a CDR-H1 comprising the amino acid sequence of GYSFTSYWIG (SEQ ID NO: 10);
(b) a CDR-H2 comprising the amino acid sequence of FIYPGDSDTRYSPSFQG (SEQ ID NO: 11);
(c) a CDR-H3 comprising the amino acid sequence of ARGILRYFDWFLDY (SEQ ID NO: 4);
(d) a CDR-L1 comprising the amino acid sequence of RASQGISSGSA (SEQ ID NO: 12);
(e) a CDR-L2 comprising the amino acid sequence of DVSSLES (SEQ ID NO: 7); and
(f) a CDR-L3 comprising the amino acid sequence of QQFNSYLLT (SEQ ID NO: 8).
US Pat. No. 10,456,439

NK3 AGONIST FOR USE IN THE TREATMENT OF A PATIENT SUFFERING FROM ATRIAL ARRHYTHMIA OR FIBRILLATION

Academisch Medisch Centru...

1. A method for treating atrial arrhythmia comprising administering to a subject in need thereof an NK3 agonist selected from the group consisting of Neurokinin B (NKB), Neurokinin A (NKA), Hemokinin 1 (HEK1), Eledoisin, Kassinin, Senktide [succinyl-(Asp6, MePhe8)-SP(6-11)], [MePhe7]-NKB (1a), Pro7-NKB, and a pharmaceutically acceptable salt thereof.
US Pat. No. 10,457,722

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE

Corixa Corporation, Seat...

1. A method of detecting inflammatory bowel disease in a subject, the method comprising:(a) obtaining a biological sample from the subject, wherein the biological sample is a serum sample;
(b) contacting the biological sample with a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs:79-82;
(c) detecting an amount of an antibody in the biological sample that binds to the polypeptide; and
(d) comparing the amount of bound antibody to a predetermined cut-off value, wherein the presence of at least one type of inflammatory bowel disease is detected when the amount of bound antibody is higher than the cut-off value.
US Pat. No. 10,457,978

CYCLOPENTANE-PEPTIDE NUCLEIC ACIDS FOR QUALITATIVE AND QUANTITATIVE DETECTION OF NUCLEIC ACIDS

The United States of Amer...

1. A method of detecting HIV-1 RNA in a solution obtained from a tissue or blood sample obtained from a human patient, the method comprising(a) providing a solution of HIV-1 RNA isolated from the tissue or blood sample,
(b) contacting the solution with a PNA capture probe and a PNA reporter probe; wherein
(i) the PNA capture probe comprises at least two trans-cyclopentanes and 15 nucleobases;
(ii) the PNA reporter probe comprises 6-30 biotin groups and 12 nucleobases, wherein the biotin groups are each attached to the PNA reporter probe via at least one mPEG (8-amino-3,6-dioxaoctanoic acid) linker group;
(iii) the PNA capture probe is bound to a surface at a N-terminus via covalent binding to form a surface-bound PNA capture probe, wherein the surface is a well of a multiwell plate comprising a polystyrene surface having a surface-attached quinone moiety comprising a (poly)ethyleneglycol-linker-attached electrophilic moiety, wherein the electrophilic moiety is reactive with amino groups; and
(iv) the PNA capture probe and the PNA reporter probe each comprise a nucleobase sequence that is complementary to different non-overlapping portions of the HIV-1 RNA;
(d) washing the surface-bound PNA capture probe;
(e) contacting the surface-bound PNA capture probe with horseradish peroxidase-avidin-conjugate or horseradish peroxidase-streptavidin-conjugate to form a complex;
(f) contacting the complex with tetramethylbenzidine and peroxide; and
(g) determining an emergence of an absorbance of visible light at a wavelength of 652 nm spectrometrically or determining an appearance of a blue color by visual observation, wherein the emergence of absorbance or the appearance of the blue color indicates the presence of a complex formed from the surface-bound PNA capture probe, the PNA reporter probe, the horseradish peroxidase-avidin-conjugate or horseradish peroxidase-streptavidin-conjugate, and the HIV-1 RNA, wherein the emergence of the absorbance of visible light at a wavelength of 652 nm or appearance of the blue color arises from oxidation of tetramethylbenzidine by horseradish peroxidase-avidin-conjugate or horseradish peroxidase-streptavidin-conjugate present in the complex;
wherein the presence of the HIV-1 RNA in the tissue or blood sample permits the detection of HIV in the patient,
wherein the HIV-1 RNA is detected when 5 to 100 copies of the HIV-1 RNA are present in the solution being tested.
US Pat. No. 10,456,440

ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS

ATRIVA THERAPEUTICS GMBH,...

1. A method for inhibiting a Staphylococcus aureus infection and an influenza virus infection in a cell comprising contacting the cell with an effective amount of a MEK inhibitor, a p38 inhibitor and/or an NF?B inhibitor.
US Pat. No. 10,457,723

IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES

1. An anti-SpA variant IgG antibody comprising:a light chain variable domain and a heavy chain variable domain comprising an antigen recognition region having antigen-specific immune binding to S. aureus protein A (SpA); and
a variant immunoglobulin heavy chain constant region that differs from that of a parent heavy chain constant region by one or more amino acid substitutions, wherein the parent heavy chain constant region includes a CH1 sequence comprising SEQ ID NO:68m, a CH2 sequence comprising SEQ ID NO:76, and a CH3 sequence comprising SEQ ID NO:80;
wherein the one or more amino acid substitutions comprise:
(i) a substitution of H at EU position of 435 with an R (H435R);
a substitution of Y at EU position of 436 with an F (Y436F); or
a substitution of H435R and Y436F; and
(ii) an amino acid substitution that attenuates non-immune binding of S. aureus Fc binding protein, SSL10.
US Pat. No. 10,461,309

METHOD FOR MANUFACTURING ELECTRODE

ASUSTeK COMPUTER INC., T...

1. A method for manufacturing an electrode, comprising:providing a composite material including a carrier layer and a collector layer disposed on the carrier layer, wherein the collector layer includes a first surface and a second surface opposite to each other, and the first surface of the collector layer faces to the carrier layer;
performing a first coating process to coat a first electrode material on the second surface of the collector layer;
performing a first curing process to dry the first electrode material;
removing the carrier layer to expose the first surface of the collector layer after the first electrode material is dried;
performing a second coating process to coat a second electrode material on the first surface of the collector layer, wherein a material of the second electrode material is same with the material of the first electrode material;
performing a second curing process to dry the second electrode material;
providing another carrier layer on a surface of the dried first electrode material far away from the collector layer after the carrier layer is removed and before the second coating process is performed, wherein the another carrier layer is configured on the surface of the collector layer via a release layer; and
removing the another carrier layer and the release layer to expose the surface of the first electrode material after the second electrode material is dried.
US Pat. No. 10,456,441

AUGMENTING THE IMMUNE RESPONSE BY PROMOTING CELL DEATH OF IMMUNE CELLS

The University of Vermont...

1. A method for treating cancer in a subject, comprising administering to a subject having cancer a caspase inhibitor and a cancer antigen in an effective amount to treat the cancer.
US Pat. No. 10,456,953

DEVICE AND METHOD FOR CYCLE- AND COST-OPTIMIZED THERMAL TRANSFORMATION OF HOSE BLANKS

1. Method for the thermal reshaping of hose blanks consisting of elastic raw hose material, wherein the hose blank is located in a hollow, single- or multi-part molding tool during the reshaping, wherein the inner side of the hollow mold corresponds as a negative to the shape that is to be impressed upon the hose blank, characterized in that the tempering of the molding tool that is necessary for reshaping occurs by means of tempering elements with half or partial shells which close form-fittingly over the mold, and the inner sides of said shells that face the molding tool are congruent with the outer side of said molding tool, wherein no tempering device, no ducts or other hollow spaces for circulating a tempering medium at all are integrated into the molding tool itself, and wherein the temperature of each tempering element is kept constant during the process, while, to modify the temperature of the molding tool, a different tempering element with a different constant temperature is positioned against the molding tool.
US Pat. No. 10,457,724

METHODS OF TREATING S. AUREUS-ASSOCIATED DISEASES

MedImmune, LLC, Gaithers...

1. A method for preventing or reducing the severity of S. aureus-associated sepsis in a mammalian subject comprising administering to said subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, wherein the isolated antibody or antigen-binding fragment thereof immunospecifically binds to a Staphylococcus aureus alpha toxin polypeptide and includes:(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 7, 10, 13 or 69;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 8, 11, 14, 17, 70 or 75;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 9, 12, 15, 18, 16, 65, 66, 67, 71, 72, 76 or 78;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or 4;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 2, 5, 73 or 77; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 3, 6, 64, 68 or 74.
US Pat. No. 10,457,980

MULTIPLEX LABELING OF MOLECULES BY SEQUENTIAL HYBRIDIZATION BARCODING

California Institute of T...

1. A method of providing a unique molecular barcode for each unique nucleic acid molecule in a plurality of nucleic acid molecules in a sample, comprising the steps of:(a) performing a first contacting step that involves contacting the sample with a first plurality of detectably labeled oligonucleotides, each of which targets a nucleic acid molecule and is labeled with a detectable moiety, so that the first plurality comprises at least:
(i) a first oligonucleotide targeting a first nucleic acid molecule and labeled with a first detectable moiety; and
(ii) a second oligonucleotide targeting a second nucleic acid molecule and labeled with a second detectable moiety;
(b) imaging the sample after the first contacting step so that interaction by oligonucleotides of the first plurality with their target sequences is detected;
(c) performing a second contacting step that involves contacting the sample with a second plurality of detectably labeled oligonucleotides, which second plurality includes oligonucleotides targeting nucleic acid molecules that are targeted by the first plurality so that the second plurality comprises at least:
(i) a third oligonucleotide, optionally identical in sequence to the first oligonucleotide, targeting the first nucleic acid molecule; and
(ii) a fourth oligonucleotide, optionally identical in sequence to the second oligonucleotide, targeting the second nucleic acid molecule,
wherein the second plurality differs from the first plurality in that at least one of the oligonucleotides present in the second plurality is labeled with a different detectable moiety than the corresponding oligonucleotide targeting the same nucleic acid molecule in the first plurality, so that, in the second plurality:
(iii) the third oligonucleotide is labeled with the first detectable moiety, the second detectable moiety or a third detectable moiety; and
(iv) the fourth oligonucleotide is labeled with the first detectable moiety, the second detectable moiety, the third detectable moiety, or a fourth detectable moiety,
wherein either the third oligonucleotide is labeled with a different detectable moiety than was the first oligonucleotide, or the fourth oligonucleotide is labeled with a different detectable moiety than was the second oligonucleotide, or both;
(d) imaging the sample after the second contacting step so that interaction by oligonucleotides of the second plurality with their target nucleic acid molecules is detected; and
(e) optionally repeating the contacting and imaging steps, each time with a new plurality of detectably labeled oligonucleotides comprising oligonucleotides that target nucleic-acid molecules targeted by the first and second pluralities, wherein each utilized plurality differs from each other utilized plurality, due to at least one difference in detectable moiety labeling of oligonucleotides targeting the same nucleic acid molecule,
wherein steps (a) to (e) produce a unique molecular barcode for each unique nucleic acid molecule in the sample.
US Pat. No. 10,457,725

METHODS OF TREATING SKIN CANCER BY ADMINISTERING A PD-1 INHIBITOR

Regeneron Pharmaceuticals...

1. A method of treating or inhibiting the growth of a tumor comprising:(a) selecting a patient with cutaneous squamous cell carcinoma (CSCC); and
(b) administering to the patient a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds PD-1, wherein the therapeutically effective amount is administered once every two weeks in a dose comprising 1 to 3 mg/kg of the patient's body weight;
wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,457,981

HYBRIDIZATION BUFFERS

Abbott Molecular Inc., D...

1. A hybridization buffer composition comprising, by weight, about 29.1% dextran sulfate, about 0.23% sodium citrate, about 0.45% sodium chloride, about 34.2% formamide, about 12.3% guanidinium thiocyanate, and about 23.7% water.
US Pat. No. 10,456,443

PEPTIDYL CALCINEURIN INHIBITORS

Ohio State Innovation Fou...

1. A composition, comprising a peptide 7 to 100 amino acids in length comprising the amino acid sequence SEQ ID NO:1, and wherein the composition inhibits calcineurin (CN) —nuclear factor of activated T cell (NFAT) signaling.
US Pat. No. 10,457,726

ANTIBODY AND ANTIGEN-BINDING FRAGMENT COMPOSITIONS TARGETING CELL SURFACE ANTIGENS IN TUMORS AND METHODS OF USE THEREOF

UNIVERSITY OF CONNECTICUT...

1. An isolated antibody or antigen-binding fragment comprising a heavy chain variable region comprising three heavy chain complementary determining regions (HCDRs), wherein the sequence of HCDR1 is GYRLSELS (SEQ ID NO: 1), the sequence of HCDR2 is ISGWDGNT (SEQ ID NO: 2), and the sequence of HCDR3 is ARASGYNY(SEQ ID NO: 3), wherein the isolated antibody or antigen-binding fragment specifically binds human HSP90.
US Pat. No. 10,457,982

METHOD FOR NUCLEIC ACID AMPLIFICATION

RIKEN, Saitama (JP)

1. A method for amplifying a nucleic acid, comprising:incubating a mixture comprising:
template RNA,
a primer,
a degrading enzyme specific to DNA in a RNA-DNA hybrid,
an RNase H minus reverse transcriptase, and
a substrate,
synthesizing a complementary DNA (cDNA) of the template RNA by the RNA-dependent DNA polymerase activity of the RNase H minus reverse transcriptase, then randomly cleaving the cDNA strand in the hybrid strand of RNA and cDNA by the degrading enzyme specific to DNA in RNA-DNA hybrid, then separating the cDNA strand on the 3? side from the RNA by the strand displacement activity of the RNase H minus reverse transcriptase, while using the cleavage site as a starting point, and then synthesizing a new cDNA in a portion separated by the RNase H minus reverse transcriptase to amplify cDNA in a reverse transcription reaction,
wherein the degrading enzyme specific to DNA in the RNA-DNA hybrid has an activity of cleaving a DNA strand in the RNA-DNA hybrid.
US Pat. No. 10,456,444

PIRIN POLYPEPTIDE AND IMMUNE MODULATION

4D PHARMA RESEARCH LIMITE...

1. A composition comprising an effective unit dose of an isolated pirin-related polypeptide of Bacteroides thetaiotaomicron, wherein said isolated polypeptide comprises an amino acid sequence having at least 95% sequence identity to the polypeptide sequence of SEQ ID NO: 2 as determined by a sequence alignment performed using a Basic Local Alignment Search Tool algorithm with a gap open penalty of 0, a gap extension penalty of 0, and a Blocks Substitution Matrix of 62, wherein the isolated pirin-related polypeptide is encapsulated as an enterically resistant capsule for delivery to the intestine.
US Pat. No. 10,457,727

METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS

ALDERBIO HOLDINGS LLC, L...

1. A rabbit anti-human nerve growth factor (NGF) antibody or antigen binding fragment which comprises the light chain CDR polypeptide sequences of SEQ ID NO: 95; SEQ ID NO: 96; and SEQ ID NO: 97 and the heavy chain CDR polypeptide sequences of SEQ ID NO: 98; SEQ ID NO: 99; and SEQ ID NO: 100.
US Pat. No. 10,461,313

NONAQUEOUS ELECTROLYTE BATTERY, BATTERY MODULE, AND BATTERY PACK

KABUSHIKI KAISHA TOSHIBA,...

1. A nonaqueous electrolyte battery comprising:a container;
a nonaqueous electrolyte provided in the container;
a positive electrode provided in the container, the positive electrode comprising a positive electrode current collector containing Al, and a positive electrode active material containing layer formed on the positive electrode current collector comprising particles represented by LixNi1-y-zCoyMnzO2(0?x?1.1, 0?y?0.5, 0 a negative electrode provided in the container, the negative electrode comprising a negative electrode current collector containing Al, and a negative electrode active material containing layer which is formed on the negative electrode current collector comprising titanium-containing oxide particles having an average particle size of primary particles of the titanium-containing oxide particles is 1 ?m or less and an average secondary particle size from 6 ?m to 20 ?m,
wherein Lp is a thickness of the positive electrode current collector and Lp is from 6 ?m to 15 ?m, and
Ln is a thickness of the negative electrode current collector and Ln is from 10 ?m to 17 ?m.
Lp and Ln are selected such that the following formula (1) is satisfied:
Lp wherein the nonaqueous electrolyte battery, satisfies the following formula (2):
(PW/NW)?(NC/PC4)  (2)
wherein the PW is a weight(g) of the positive electrode active material containing layer, and the NW is a weight(g) of the negative electrode active material containing layer, the PC4 is a charging capacity per weight (mAh/g) when a maximum charging voltage of the positive electrode is 4 V with reference to a Li potential (vs. Li/Li?), and the NC is a charging capacity per weight (mAh/g) when a charging voltage of the negative electrode is 1 V with reference to the Li potential (vs. Li/Li+).
US Pat. No. 10,456,445

METHODS AND COMPOSITIONS FOR IMMUNOMODULATION

1. A method of suppressing allograft rejection, the method comprising administering a therapeutically effective amount of a Semaphorin 3F (Sema3F) agonist to an allograft recipient, whereby immune rejection of the allograft is suppressed, anda. wherein the Sema3F agonist is a Sema3F polypeptide that binds to a Sema3F receptor, or
b. wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide that binds to a Sema3F receptor.
US Pat. No. 10,457,728

COMPOUNDS AND METHODS FOR TREATING PAIN

MedImmune Limited, Cambr...

1. A binding molecule comprising an NGF antagonist domain and a TNF? antagonist domain, wherein the NGF antagonist domain comprises an anti-NGF antibody or fragment thereof; wherein the TNF? antagonist domain comprises a soluble, TNF?-binding fragment of TNFR-2; wherein the anti-NGF antibody or fragment thereof comprises a VH domain comprising a set of CDRs HCDR1, HCDR2, HCDR3 and a VL domain comprising a set of CDRs LCDR1, LCDR2 and LCDR3, wherein the HCDR1 has the amino acid sequence of SEQ ID NO: 4, the HCDR2 has the amino acid sequence of SEQ ID NO: 5, the HCDR3 has the amino acid sequence of any one of SEQ ID NOs: 6, 11 or 12, the LCDR1 has the amino acid sequence of SEQ ID NO: 8, the LCDR2 has the amino acid sequence of SEQ ID NO: 9, and the LCDR3 has the amino acid sequence of SEQ ID NO: 10; wherein a cysteine is present in the VH domain at the amino acid corresponding to amino acid position 44 of SEQ ID NO: 94; and wherein a cysteine is present in the VL domain at the amino acid corresponding to amino acid position 103 of SEQ ID NO: 95.
US Pat. No. 10,456,446

USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE

Korea University Research...

1. A screening method to determine if a medicine can prevent or treat bone disease, comprising:contacting a cell transformed with human small leucine-zipper proteins (sLZIP) and Peroxisome proliferator-activated receptor ?2 (PPAR?2) with a candidate material, wherein either the human sLZIP or PPAR?2 is coupled to a detectable component; and
detecting an increase in formation of the complex of the human sLZIP and PPAR?2 in the cell, whereby said candidate material is determined to be a material capable of preventing or treating bone disease.
US Pat. No. 10,456,958

METHOD FOR PRODUCING SYNTHETIC LEATHER AND SYNTHETIC LEATHER PRODUCED BY THE SAME

Soon Kie Jung, Glen Sadd...

1. A method for producing synthetic leather, the method comprising:(a) a first coating process of knife-coating a release paper with a first coating liquid including a first silicone rubber having a viscosity of 100 Pa·s or more, an elongation of 300% or more, and a shore A hardness of 50 or more;
(b) a second coating process of knife-coating the release paper coated with the first coating liquid with a second coating liquid including a second silicone rubber having a viscosity of 100 Pa·s or more, an elongation of 300% or more, and a shore A hardness of less than 50;
(c) a bonding process of bonding the release paper coated with the second coating liquid with a fabric, followed by drying and curing; and
(d) a separation process of separating the release paper from the coated fabric bonded onto the release paper.
US Pat. No. 10,457,729

COMPOSITIONS AND METHODS FOR TREATING CANCER

The Trustees of the Unive...

1. An isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence comprises a nucleic acid sequence encoding an ?-folate receptor (FR?) antibody comprising the amino acid sequence of SEQ ID NO: 23.
US Pat. No. 10,457,985

METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE POLYNUCLEOTIDE TEMPLATES

Illumina Cambridge Limite...

1. A method for sequencing nucleic acid sequences and identifying subsets of nucleic acid sequences, each subset of nucleic acid sequences isolated from a different source, the method comprising the steps of:(a) providing at least two different samples of randomly fragmented double stranded nucleic acid targets, wherein each of the randomly fragmented double stranded nucleic acid targets is isolated from a different source;
(b) ligating a sample specific tagged adaptor to each end of each target fragment of each sample to generate adaptor-target-adaptors, wherein the tagged adaptor comprises at least one region of single stranded nucleic acid and a region of double stranded nucleic acid comprising a sample specific tag sequence that differentiates adaptor-target-adaptors originating from different samples, and wherein the sample specific tag sequence is attached directly to the target fragment in each adaptor-target-adaptor with no intervening nucleotides;
(c) amplifying the adaptor-target-adaptors of each sample with a pair of amplification primers complementary to the sample specific tag sequence to generate amplified adaptor-target-adaptors from each sample;
(d) pooling the amplified adaptor-target-adaptors of the at least two different samples;
(e) immobilizing the pooled adaptor-target-adaptors on a surface;
(f) sequencing the immobilized adaptor-target-adaptors on the surface to determine a sequence read of each immobilised adaptor-target-adaptor and identify the sample specific tag sequence of each immobilised adaptor-target-adaptor, thereby determining nucleic acid sequences of the immobilized adaptor-target-adaptors and identifying each of the immobilized adaptor-target-adaptors as a member of a subset of nucleic acid sequences.
US Pat. No. 10,456,447

THERAPEUTIC MODULATION OF SKIN IMMUNE SYSTEM WITH GAL-7

1. A method for treating psoriasis comprising, administering to an individual in need thereof an effective amount of Gal-7, thereby treating the psoriasis.
US Pat. No. 10,457,730

CHIMERIC ANTIGEN RECEPTOR (CAR) COMPRISING A CD19-BINDING DOMAIN

UCL BUSINESS PLC, London...


US Pat. No. 10,457,986

METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES

10X GENOMICS, INC., Plea...

1. A method for analyzing analytes comprising:(a) providing a first analyte, a second analyte, a cell feature binding group comprising a reporter molecule comprising a reporter barcode sequence associated with said cell feature binding group, and a support having coupled thereto a plurality of nucleic acid barcode molecules,
wherein said second analyte is a different type of analyte than said first analyte,
wherein said cell feature binding group is configured to couple to said first analyte, and
wherein said plurality of nucleic acid barcode molecules comprise (i) a common barcode sequence and (ii) a common capture sequence; and
(b) generating:
(i) a first barcoded nucleic acid molecule comprising: (1) a first sequence corresponding to said reporter barcode sequence and (2) a second sequence corresponding to said common barcode sequence, and
(ii) a second barcoded nucleic acid molecule comprising: (1) a third sequence corresponding to said second analyte and (2) a fourth sequence corresponding to said common barcode sequence.
US Pat. No. 10,456,448

PTD-SMAD7 THERAPEUTICS

The Regents of the Univer...

1. A protein molecule comprising a protein transduction domain and a human mothers against decapentaplegic-7 protein (Smad7) fragment comprising amino acids 203-258 of the human Smad7 protein, wherein the Smad7 fragment retains one or more biological activities of the functional full-length Smad7 protein, and with the proviso that the protein molecule lacks at least amino acids 1 to 25 of the human Smad7 protein.
US Pat. No. 10,457,731

MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF

bluebird bio, Inc., Camb...

1. An isolated non-natural cell, comprising:(a) a first exogenous polynucleotide encoding a first fusion protein comprising a first multimerization domain, a first transmembrane domain, and an actuator domain, wherein the first multimerization domain localizes extracellularly when the first fusion protein is expressed; and
(b) a second exogenous polynucleotide encoding a second fusion protein comprising a secretion signal; a binding domain that comprises a single chain antibody, a receptor ectodomain, or a ligand; a second multimerization domain; and a second transmembrane domain, wherein the binding domain and the second multimerization domain localizes extracellularly when expressed;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second fusion proteins.
US Pat. No. 10,458,756

FLEXIBLE ADHESIVE BALLISTIC SHIELD

1. A flexible ballistic shield having an adhesive surface for bonding the ballistic shield to a substrate, the ballistic shield comprising at least a base layer of a bonding butyl rubber material and at least a first layer of a ballistic fabric material disposed on an outer-facing surface of the base layer of bonding butyl rubber material, the inner-facing surface of the base layer providing the adhesive surface of the ballistic shield, the bonding butyl rubber material comprising: a butyl rubber selected from the group consisting of polyisobutene, a copolymer of isobutylene and isoprene, and a combination thereof, for attaching the ballistic shield to a substrate of a vehicle or structure, wherein the adhesive, cohesive and elastic qualities of the butyl rubber material penetrate into the threads of the ballistic fabric, and adhere the base surface of the ballistic shield tenaciously to a surface of a substrate.
US Pat. No. 10,456,449

METHODS AND USES FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES

NGM Biopharmaceuticals, I...

1. A method of reducing bile acid synthesis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of(i) a polypeptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO:70, and
(ii) at least one additional agent, wherein the additional agent is an anti-CD20 agent, an anti-CD80 agent, an anti-cytokine antibody, an anti-retroviral therapy, an apical sodium bile acid transporter (ASBT) inhibitor, an autoimmune agent, azathioprine, cochicine, a CSCL10 neutralizing antibody, a CXCR3 ligand, cyclosporine, a cytokine anti-inflammatory drug (CSAID), a cytokine, a growth factor, a fibrate, a fish oil, an immune checkpoint inhibitor, or a non-steroidal anti-inflammatory drug (NSAID);
thereby reducing bile acid synthesis in the subject without inducing HGG hepatocellular carcinoma (HCC) formation.
US Pat. No. 10,457,732

BISPECIFIC BINDING PROTEINS AND USES THEREOF

MEDIMMUNE, LLC, Gaithers...

1. A bispecific binding protein that binds to PD-1 and CTLA-4 comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 9, a first light chain comprising the amino acid sequence of SEQ ID NO: 7, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and a second light chain comprising the amino acid sequence of SEQ ID NO: 4.
US Pat. No. 10,457,988

MIRNAS AS DIAGNOSTIC MARKERS

Siemens Aktiengesellschaf...

1. A pharmaceutical composition containing an isolated nucleic acid molecule consisting of SEQ ID NO:270, wherein at least one nucleotide of the isolated nucleic acid molecule is a modified nucleotide or nucleotide analog.
US Pat. No. 10,458,500

FRICTION MATERIAL

Nisshinbo Brake Inc., To...

1. A friction material which is a non-asbestos-organic friction material utilized for a disc brake pad, which is manufactured by forming a non-asbestos organic friction material composition that does not contain a copper component, whereinsaid friction material composition contains
4-12 weight % of a binder relative to the total amount of the friction material composition, said binder consists of one or any combination of two or more items selected from the group consisting of a straight phenolic resin, a cashew oil modified phenolic resin, a silicone oil modified phenolic resin, an elastomer modified phenolic resin, an aralkyl modified phenolic resin, an elastomer dispersed phenolic resin, and a fluoropolymer dispersed phenolic resin,
7-35 weight % of a titanate relative to the total amount of the friction material composition,
0.5-10 weight % of a resilient graphitic carbon particle relative to the total amount of the friction material composition as a carbon type lubricant,
1-15 weight % of a ferrous sulfide relative to the total amount of the friction material composition as a metal sulfide type lubricant, and
1-10 weight % of an inorganic friction modifier, said modifier is one or any combination of two or more items selected from the group consisting of an alloy particle mainly containing aluminum, and an alloy fiber mainly containing aluminum relative to the total amount of the friction material composition as an inorganic friction modifier.
US Pat. No. 10,457,733

AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF

Dana-Farber Cancer Instit...

1. A method for upregulating an immune response comprising contacting a cell expressing RGMb with an agent that inhibits the interaction of PD-L2 with RGMb to thereby upregulate the immune response, wherein the agent is a blocking monoclonal antibody that binds RGMb, or an antigen-binding fragment thereof, comprising six CDRs: CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3, wherein the CDR-L1 sequence consists of amino acid residues 44-54 of SEQ ID NO:12, CDR-L2 sequence consists of amino acid residues 70-76 of SEQ ID NO:12, the CDR-L3 sequence consists of amino acid residues 109-116 of SEQ ID NO:12, the CDR-H1 sequence consists of amino acid residues 50-54 of SEQ ID NO:14, the CDR-H2 sequence consists of amino acid residues 69-85 of SEQ ID NO:14, and the CDR-H3 sequence consists of amino acid residues 118-125 of SEQ ID NO:14.
US Pat. No. 10,457,989

METHOD OF DOUBLE ALLELE SPECIFIC PCR FOR SNP MICROARRAY

Phalanx Biotech Group, In...

1. A method of double allele specific polymerase chain reaction (PCR) for single nucleotide polymorphism (SNP) microarray, comprising:(a) amplifying a nucleic acid sample by multiplex SNP PCR using at least a primer set which recognizes a single nucleotide polymorphism (SNP) to obtain an amplified product; wherein an interchelating agent is added into PCR to inhibit non-specific amplification, and the interchelating agent is N?,N?-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine; and
(b) contacting the amplified product with a SNP microarray fixed probe suitable for determining the identity of SNP to genotype SNP,
wherein the primer set contains at least four allele specific primers, which at least two allele specific primers bound with a sense strand of the nucleic acid sample, and 3? terminal nucleotides of the two allele specific primers are complementary to an allele specific site; and at least two allele specific primers bound with an antisense strand of the nucleic acid sample, and 3? terminal nucleotides of the two allele specific primers are complementary to the allele specific site;
wherein the allele specific primers have melting temperature (Tm) values, and the Tm values have maximum temperature difference of 2.8° C. in single PCR.
US Pat. No. 10,456,451

PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE


wherein
X3 is any amino acid;
X4 is serine or valine;
X5 is leucine, praline, threonine, or valine; and
X6 is any amino acid residue,
and wherein
(a) Xp is a proteinogenic amino acid(s) or a protease protective organic group and p is any integer from 1 to 4;
(b) said mSDF-1 maintains chemoattractant activity for T cells and is inactivated by matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, and/or cathepsin G at a rate that is at least 50% less than the rate of inactivation of native SDF-1;
(c) said Xp-mSDF-1 maintains chemoattractant activity for T cells, is inactivated by dipeptidyl peptidase IV (DPPIV) at a rate that is at least 50% less than the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2, MMP-9, leukocyte elastase, and/or cathepsin Gat a rate that is at least 50% less than the rate of inactivation of native SDF-1; and
(d) said mSDF-1 or Xp-mSDF-1 peptide does not comprise the amino acid sequence of at least amino acids 1-8 of SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60, or SEQ ID NOs: 65-67.
US Pat. No. 10,457,734

IGF-1R ANTIBODY AND ITS USE FOR THE DIAGNOSIS OF CANCER

PIERRE FABRE MEDICAMENT, ...

1. An IGF-1R antibody, or an antigen-binding fragment thereof, said antibody comprising:i) a heavy chain comprising the following three CDRs, respectively CDR-H1 of sequence SEQ ID No. 1, CDR-H2 of sequence SEQ ID No. 2 and CDR-H3 of sequence SEQ ID No. 3; and
ii) a light chain comprising the following three CDRs, respectively CDR-L1 of sequence SEQ ID No. 4, CDR-L2 of sequence SEQ ID No. 5 and CDR-L3 of sequence SEQ ID No. 6.
US Pat. No. 10,456,452

COMPOSITIONS AND METHODS FOR IMPROVED ENCAPSULATION OF FUNCTIONAL PROTEINS IN POLYMERIC VESICLES

Poseida Therapeutics, Inc...

1. A composition, comprising:a suspension of a polymersome-encapsulated functional protein, wherein the suspension is prepared by:
thermally blending a quantity of an amphiphilic diblock copolymer with a quantity of polyethylene glycol (PEG), wherein the amphiphilic diblock copolymer comprises poly(ethylene oxide)-block-poly(butadiene) (PEO-b-PBD);
adding an aliquot of a solution of the functional protein to a sample containing the PEG/polymer formulation, wherein the solution of the functional protein comprises oxymyoglobin or metmyoglobin in phosphate buffered saline (PBS); and
performing at least one dilution step such that polymersomes that are generated are progressively saturated with the functional protein.
US Pat. No. 10,457,991

COMPOSITIONS AND METHODS FOR IDENTIFYING DEPRESSIVE DISORDERS

Northwestern University, ...

1. A panel of biomarkers consisting of an isolated set of 100 or fewer full-length cDNA biomarkers, wherein said isolated set includes DAG1 , CTSB, and TMCC2 full-length cDNA biomarkers.
US Pat. No. 10,456,453

USE OF ANGIOGENIN OR ANGIOGENIN AGONISTS FOR TREATING DISEASES AND DISORDERS

AGRICULTURE VICTORIA SERV...

1. A method of treating a subject having weakness or loss of weight caused by a disease or as a side effect of an illness, the method comprising administering to the subject in need thereof an effective amount of a composition comprising angiogenin, wherein the subject is a human, cat, dog, sports animal, food source animal, or avian species, andwherein
the composition comprises angiogenin as the only active ingredient, or
the composition is a milk fraction in which the concentration of angiogenin is at least 10 times its concentration in milk and is depleted for lactoferrin and lactoperoxidase.
US Pat. No. 10,457,736

BINDING AGENTS

ULTRAHUMAN ONE LIMITED, ...

1. An antibody molecule that specifically binds to human glucocorticoid-induced TNF receptor (GITR) or an antigen-binding portion thereof, wherein the antibody molecule or antigen-binding portion comprises:(a) a heavy chain variable region comprising a HCDR1 of SEQ ID NO:29, a HCDR2 of SEQ ID NO:26, a HCDR3 of SEQ ID NO:31; and a light chain variable region comprising a LCDR1 of SEQ ID NO:32, a LCDR2 of SEQ ID NO:33, a LCDR3 of SEQ ID NO:34; or
(b) a heavy chain variable region comprising a HCDR1 of SEQ ID NO:29, a HCDR2 of SEQ ID NO:26, a HCDR3 of SEQ ID NO:31; and a light chain variable region comprising a LCDR1 of SEQ ID NO:32, a LCDR2 of SEQ ID NO:44, a LCDR3 of SEQ ID NO:34.
US Pat. No. 10,457,992

HYPERMETHYLATION BIOMARKERS ASSOCIATED WITH POOR SURVIVAL OUTCOMES FOR HEAD AND NECK SQUAMOUS CELL CANCER

The Johns Hopkins Univers...

1. A method for identifying an increased risk for a poor survival outcome in a subject having head and neck squamous cell cancer comprising:a) obtaining nucleic acid from a test sample from the subject, wherein the test sample is from a specimen selected from the group consisting of a tissue specimen, a biopsy specimen, a surgical specimen, saliva, and a cytological specimen;
b) performing bisulfite modification to the nucleic acid in a);
c) performing quantitative methylation specific PCR (QMSP) on bisulfite modified nucleic acid from b) using PCR primers and probes specific for the promoter region of one or more genes of interest, wherein the one or more genes of interest are selected from the group consisting of PAX1, PAX5, ZIC4, and PLCB1, and the primers and probes are selected from the group consisting of SEQ ID NOS: 4-15;
d) determining the promoter methylation level of the promoter regions of the one or more genes of interest in the nucleic acid from the test sample of the subject;
e) providing a reference non-neoplastic sample, wherein the reference non-neoplastic sample is from a specimen selected from the group consisting of a tissue specimen, a biopsy specimen, a surgical specimen, saliva, and a cytological specimen;
f) comparing the level of promoter methylation of the one or more genes of interest from the test sample of the subject, to the level of promoter methylation of the one or more genes of interest in a reference non-neoplastic sample;
g) identifying an increased risk of poor survival outcome for the subject having head and neck squamous cell cancer when the level of promoter methylation of the one or more genes of interest in the test sample of the subject, is increased relative to the level of promoter methylation of the one or more genes of interest in the reference non-neoplastic test indicating epigenetic silencing of the one or more genes of interest; and
h) adjusting or modifying the planned treatment of the subject as a result of the increased risk of poor survival in the subject having head and neck squamous cell cancer.
US Pat. No. 10,456,454

CNS DELIVERY OF THERAPEUTIC AGENTS

Shire Human Genetic Thera...

1. A formulation for intrathecal administration comprising a lysosomal enzyme at a concentration at or greater than about 5 mg/ml, and a surfactant, wherein the formulation comprises phosphate at a concentration of no greater than 50 mM.
US Pat. No. 10,457,737

ENGINEERED IMMUNOGLOBULIN FC POLYPEPTIDES DISPLAYING IMPROVED COMPLEMENT ACTIVATION

Research Development Foun...

1. A polypeptide comprising an aglycosylated variant human IgG Fc domain capable of binding human C1q, wherein the Fc domain comprises amino acid substitutions selected from the group consisting of:(a) K320E and Q386R,
(b) L235K, G236M, G237R, and L351Q,
(c) V308A, S337P, K338Q, K340R, Q342P, R344G, E345Y, and F372L,
(d) M252V, G341A, and L351Q,
(e) M252V, K246N, K322E, R344G, E345Y, and F372L,
(f) M252V, F242L, K338Q, G341A, and E345Y, and
(g) F242L, M252V, K338Q, G341A, and E345Y;wherein the numbering of the residues in the Fc domain is that of the EU index as in Kabat.
US Pat. No. 10,457,993

BIOMARKER RNF6 FOR COLORECTAL CANCER

The Chinese University of...

1. A method for assessing risk for colon cancer, comprising the steps of:(a) performing a polymerase chain reaction (PCR) to determine RNF6 level in a colon tissue sample taken from a human subject, wherein the RNF6 level is genomic RNF6 level or RNF6 mRNA level, and wherein a primer comprising the nucleotide sequence of SEQ ID NO:1 or 2 is used in the PCR;
(b) comparing the RNF6 level obtained in step (a) with a standard control level obtained from a non-cancer colon tissue sample; and
(c) determining the subject, who has an increased RNF6 level compared with the standard control level, as having an increased risk for colon cancer.
US Pat. No. 10,456,455

TREATMENT OF PSYCHOLOGICAL TRAUMA

Allergan, Inc., Irvine, ...

1. A method of treating at least one symptom of post-traumatic stress disorder in a patient in need thereof, the method comprising the step of administering to the patient a therapeutically effective amount of a composition including a botulinum neurotoxin (BoNT), wherein administration of the composition decreases the at least one symptom of the post-traumatic stress disorder; and wherein the at least one symptom of post-traumatic stress disorder comprises total or partial amnesia of a traumatic event, flashbacks or nightmares wherein the patient re-experiences the traumatic event, avoidance of stimuli associated with the traumatic event, increased arousal including difficulty falling or staying asleep, anger, hyper-vigilance, or combinations thereof.
US Pat. No. 10,457,738

STIMULATION VIA TLR4/MD-2 TO REVERSE TYPE 1 DIABETES

University of Cincinnati,...

1. A method of treating Type I diabetes in a subject, comprising administering an agonistic monoclonal antibody to Toll-Like Receptor 4 (TLR4).
US Pat. No. 10,457,994

4-MIRNA SIGNATURE FOR PREDICTING CLEAR CELL RENAL CELL CARCINOMA METASTASIS AND PROGNOSIS

CITY OF HOPE, Duarte, CA...

1. A method for predicting existence of or risk for developing metastasis in a renal cell carcinoma comprising:detecting a test expression level of a set of one or more miRNAs of a renal cell carcinoma-specific expression signature comprising miR-10b, miR-139-5p, miR-130b, and miR-199b-5p in a biological sample from a subject having a renal cell cancer;
assigning a risk score to the test expression level, wherein the risk score is calculated by a formula:
Risk score=?1.275564×XmiR-10b+2.106701×XmiR-130b?2.278192×XmiR-139-5p+1.101139×XmiR-199b-5p; and
predicting the existence of or a high risk for developing metastasis when the test expression level is assigned a high risk score, predicting a low risk for developing metastasis when the test expression level is assigned a low risk score.
US Pat. No. 10,456,456

ANTI-IL-6 VACCINE COMPOSITION

PEPTINOV SAS, Paris (FR)...

1. A method for reducing symptoms of an arthritic disease, comprising administering to an individual in need thereof a therapeutically effective amount of at least one cyclized polypeptide with a length equal to 25 amino acids or less, wherein the at least one cyclized polypeptide comprises, or consists of, a sequence selected from the group consisting of SEQ ID NO: 2, 3, 17, 18 and 19, and a variant sequence thereof having at least 90% sequence identity with the sequence of SEQ ID NO: 2, 3, 17, 18 or 19 and elicits a protective anti-human IL-6 immune reaction.
US Pat. No. 10,457,739

ANTI-CEACAM5 ANTIBODIES AND USES THEREOF

SANOFI, Paris (FR)

1. An isolated nucleic acid comprising a sequence encoding an antibody or antigen binding fragment thereof that binds to human CEACAM5 protein, wherein said antibody or antigen binding fragment thereof comprises a CDR1-H comprising an amino acid sequence of SEQ ID NO:7, a CDR2-H comprising an amino acid sequence of SEQ ID NO:8, a CDR3-H comprising an amino acid sequence of SEQ ID NO:9, a CDR1-L comprising an amino acid sequence of SEQ ID NO:10, a CDR2-L comprising an amino acid sequence of NTR or an amino acid sequence of NTK, and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12.
US Pat. No. 10,457,995

SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION

GUARDANT HEALTH, INC., R...

1. A method for detecting copy number variation, comprising:a) attaching a set of molecular barcodes to cell-free nucleic acid molecules obtained or derived from a sample of a subject to produce tagged parent polynucleotides, wherein a plurality of the tagged parent polynucleotides has identical molecular barcodes;
b) amplifying the plurality of the tagged parent polynucleotides, thereby producing progeny polynucleotides;
c) sequencing at least a portion of the progeny polynucleotides to generate sequence reads;
d) mapping the sequence reads derived from the sequencing to a reference sequence to produce mapped reads;
e) grouping the mapped sequence reads into families, wherein, of the families, a family corresponds to sequence reads of one or more progeny polynucleotides amplified from a same tagged parent polynucleotide of the plurality of the tagged parent polynucleotides;
f) quantifying numbers of families mapping to predefined regions of the reference sequence; and
g) determining copy number variation in one or more of the predefined regions from the numbers of families mapping to the predefined regions of the reference sequence.
US Pat. No. 10,456,457

PEPTIDE MIXTURE

TARGOVAX ASA, Oslo (NO)

1. A T-cell mixture, suitable for administration to a patient,wherein the T-cell mixture comprises T-cells specific for:
a peptide consisting of the amino acid sequence of SEQ ID NO: 19 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 20 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 21 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 22 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 23 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 24 when presented on an MHC molecule,
a peptide consisting of the amino acid sequence of SEQ ID NO: 25 when presented on an MHC molecule, and
a peptide consisting of the amino acid sequence of SEQ ID NO: 26 when presented on an MHC molecule.
US Pat. No. 10,457,740

METHODS AND COMPOSITIONS FOR TREATING CANCER USING P2RX2 INHIBITORS

Flagship Pioneering Innov...

1. A method of treating a human subject identified as having pancreatic cancer, the method comprising administering to the subject an amount of a small molecule P2RX2 antagonist effective to reduce growth of the pancreatic cancer, thereby treating the subject, wherein the small molecule P2RX2 antagonist is selected from the group consisting of CHEMBL494161, CHEMBL119416, CHEMBL604158, CHEMBL1672098, CHEMBL495204, CHEMBL 499580, CHEMBL598857, CHEMBL1671997, CHEMBL523173, CHEMBL1672107, CHEMBL597820, CHEMBL1671996, CHEMBL492300, CHEMBL523043, CHEMBL597591, CHEMBL1671993, CHEMBL494159, CHEMBL521983, CHEMBL597203, CHEMBL1671992, CHEMBL494353, CHEMBL500550, CHEMBL596982, CHEMBL134193, CHEMBL494160, CHEMBL492299, CHEMBL524284, CHEMBL133576, CHEMBL494158, CHEMBL504607, CHEMBL524064, CHEMBL131271, CHEMBL526307, CHEMBL494176, CHEMBL522725, CHEMBL118007, CHEMBL492934, CHEMBL493547, CHEMBL522053, CHEMBL116926, CHEMBL492933, CHEMBL493546, CHEMBL521709, CHEMBL492729, CHEMBL494582, CHEMBL446310, CHEMBL499428, CHEMBL521820, CHEMBL492907, CHEMBL69727, CHEMBL498038, CHEMBL494940, CHEMBL492703, CHEMBL331358, CHEMBL496229, CHEMBL492789, CHEMBL1672104, CHEMBL494833, CHEMBL496022, CHEMBL69234, CHEMBL495203, CHEMBL509572, CHEMBL495834, CHEMBL401735, CHEMBL1672105, CHEMBL496030, CHEMBL495796, CHEMBL494834, CHEMBL448525, CHEMBL1671995, CHEMBL450832, CHEMBL494832, CHEMBL271672, CHEMBL523000, CHEMBL404659, CHEMBL494772, CHEMBL496401, CHEMBL492968, CHEMBL404450, CHEMBL494181, CHEMBL413145, CHEMBL271688, CHEMBL403051, CHEMBL257495, CHEMBL119180, CHEMBL494581, CHEMBL402239, CHEMBL117766, CHEMBL502618, CHEMBL45413, CHEMBL256864, CHEMBL495195, CHEMBL444469, CHEMBL331250, CHEMBL256688, CHEMBL493740, CHEMBL1672106, CHEMBL492967, CHEMBL256057, CHEMBL492562, CHEMBL493741, CHEMBL492744, CHEMBL1672103, CHEMBL477339, CHEMBL443930, CHEMBL606414, CHEMBL1672102, CHEMBL492935, CHEMBL604300, CHEMBL1672099, CHEMBL522184, and CHEMBL492745.
US Pat. No. 10,456,458

IMMUNOGENIC COMPOSITION OF KILLED LEPTOSPIRA BACTERIA

Intervet Inc., Madison, ...

1. A composition containing an immunogenic cell preparation of killed Leptospira bacteria in an ethylenediaminetetraacetic acid solution; wherein the solution comprises 5 to 50 mmols of ethylenediaminetetraacetic acid per liter; wherein the Leptospira bacteria are selected from the group consisting of Leptospira interrogans serogroup Canicola serovar Portland-Vere, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, and Leptospira kirschneri serogroup Grippotyphosa serovar Dadas.
US Pat. No. 10,457,741

CHICKEN ANTIBODY TRANSFORMED INTO CYSTEINE AND SITE-SPECIFIC CONJUGATION USING SAME

1. An isolated cysteine-modified chicken antibody that binds to prostate specific antigen comprising at least one modified light chain framework or at least one heavy chain framework,wherein the at least one modified light chain framework comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9 to SEQ ID NO: 56 and the at least one modified heavy chain framework comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 57 to SEQ ID NO: 88.
US Pat. No. 10,457,742

STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN

ZYMEWORKS INC., Vancouve...

1. A mammalian host cell comprising nucleic acid encoding a heteromultimer comprising a modified heterodimeric CH3 domain comprising a first CH3 domain polypeptide and a second CH3 domain polypeptide, the first and second CH3 domain polypeptides independently comprising amino acid modifications as compared to a wild-type CH3 domain polypeptide,wherein the first CH3 domain polypeptide comprises amino acid modifications at positions T350, L351, F405, and Y407, and the second CH3 domain polypeptide comprises amino acid modifications at positions T350, T366, K392 and T394,
wherein the amino acid modification at position T350 is T350V, T350I, T350L or T350M; the amino acid modification at position L351 is L351Y; the amino acid modification at position F405 is F405A, F405V, F405T or F405S; the amino acid modification at position Y407 is Y407V, Y407A or Y407I; the amino acid modification at position T366 is T366L, T366I, T366V or T366M, the amino acid modification at position K392 is K392F, K392L or K392M, and the amino acid modification at position T394 is T394W
wherein the modified heterodimeric CH3 domain is comprised by a Fc construct based on a type G immunoglobulin (IgG), and
wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat.
US Pat. No. 10,456,460

VACCINE COMPOSITIONS FOR TREATMENT OF ZIKA VIRUS

Variation Biotechnologies...

1. A pharmaceutical composition comprising a virus-like particle (VLP) comprising:a first polypeptide that is a fusion protein comprising an N-terminal portion of a gag protein found in murine leukemia virus (MLV) fused upstream of a modified NS1 protein found in zika virus (ZIKV), said fusion protein having at least 95% identity with the amino acid sequence of SEQ ID NO:19;
a second polypeptide having an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 10; and
a pharmaceutically acceptable carrier.
US Pat. No. 10,457,743

ANTIBODIES RECOGNIZING THE N-TERMINAL PART OF TISSUE FACTOR PATHWAY INHIBITOR CAPABLE OF ELICITING PRO-COAGULANT ACTIVITY

1. An isolated antibody or fragment thereof comprising:said antibody or fragment thereof which specifically binds to an epitope present in amino acid residues 1 to 79 of human TFPI (SEQ ID NO: 2) comprising a heavy chain and a light chain, wherein,
the heavy chain comprises:
a CDR1 sequence corresponding to amino acids 31 to 35 of SEQ ID NO: 6 (NYGVH),
a CDR2 sequence corresponding to amino acids 50 to 65 of SEQ ID NO: 6 (VIWRGGSIDYNAAFMS), and
a CDR3 sequence corresponding to amino acids 98 to 110 of SEQ ID NO: 6 (NSHGNYVGYAMDY); and
the light chain comprises:
a CDR1 sequence corresponding to amino acids 24 to 34 of SEQ ID NO: 7 (KASQSVGPAVA),
a CDR2 sequence corresponding to amino acids 50 to 56 of SEQ ID NO: 7 (SASNRYT), and
a CDR3 sequence corresponding to amino acids 89 to 96 of SEQ ID NO: 7 (QQYTSYPT).
US Pat. No. 10,456,461

CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS

The United States of Amer...

1. A nucleic acid chimera comprising a first nucleotide sequence encoding two structural proteins from a West Nile virus, wherein the structural proteins are premembrane/membrane (prM) and envelope (E), and a second nucleotide sequence encoding capsid (C) and nonstructural proteins from a dengue type 1 virus, dengue type 2 virus, or dengue type 3 virus, wherein the dengue virus is attenuated by a deletion of about 30 nucleotides from the 3? untranslated region of the dengue genome corresponding to the TL2 stem-loop structure and wherein a cleavage site is utilized for joining the dengue virus capsid protein and the West Nile virus prM protein, and wherein the West Nile virus prM protein contains aspartic acid (Asp) at a position 3 amino acids downstream of the cleavage site and contains threonine (Thr) at a position 6 amino acids downstream of the cleavage site wherein the cleavage site corresponds to amino acid position 3 of SEQ ID NO: 3.
US Pat. No. 10,457,744

ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES

Astute Medical, Inc., Sa...


US Pat. No. 10,458,000

PLASMA AND OXYGAS FIRED FURNACE

UMICORE, Brussels (BE)

1. A process for smelting metallurgical charges, comprising:providing an apparatus comprising a bath furnace susceptible to contain a molten charge up to a determined level, characterized in that the furnace is equipped with:
at least one non-transferred plasma torch for the generation of first hot gases;
at least one oxygas burner for the generation of second hot gases gasses; and,
submerged injectors for injecting said first and second hot gases below said determined level;
feeding a metallurgical charge including transition metals and slag formers to the furnace;
smelting the charge using the oxygas burner(s) as a primary enthalpy source, thereby forming an alloy comprising a first part of the transition metals and a slag comprising a second part of the transition metals;
treating the slag in strongly reducing conditions using the plasma torch(es) as primary enthalpy source, thereby forming an alloy enriched in transition metals and a slag depleted in transition metals by transferring said second part of the transition metals from the slag to the alloy; and,
separating the alloy and the depleted slag by tapping.
US Pat. No. 10,456,462

VACCINE AGAINST RSV

1. A composition comprising a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein the polypeptide comprises SEQ ID NO: 21.
US Pat. No. 10,457,745

ANTI-COMPLEMENT C1S ANTIBODIES

Bioverativ USA Inc., Wal...

1. A humanized antibody that binds complement C1s protein and comprises:a light chain variable region that comprises a CDR-L1 amino acid sequence set forth in SEQ ID NO: 9, a CDR-L2 amino acid sequence set forth in SEQ ID NO: 10, and a CDR-L3 amino acid sequence set forth in SEQ ID NO: 11;
a heavy chain variable region that comprises a CDR-H1 amino acid sequence set forth in SEQ ID NO: 12, a CDR-H2 amino acid sequence set forth in SEQ ID NO: 13, and a CDR-H3amino acid sequence set forth in SEQ ID NO: 14; and
a human Fc region.
US Pat. No. 10,461,331

LITHIUM BATTERY

NATIONAL CHENG KUNG UNIVE...

1. A lithium battery, comprising:a hollow housing;
an anode disposed in the hollow housing;
a cathode disposed in the hollow housing;
a separator disposed between the anode and the cathode;
a liquid electrolyte filled between the anode and the separator and filled between the cathode and the separator, wherein the liquid electrolyte comprises a lithium ion composition; and
a plurality of graphene oxide quantum dots, wherein the graphene oxide quantum dots have an average particle size between 2 nm and 9 nm, wherein the liquid electrolyte or the separator comprises the graphene oxide quantum dots.
US Pat. No. 10,457,746

COMPOUNDS BINDING TO JMJD6 WITH ANTIFIBROTIC ACTIVITY

1. A monoclonal antibody or a fragment thereof,wherein the monoclonal antibody or a fragment thereof binds to JMJD6,
wherein the monoclonal antibody or a fragment thereof comprises a light chain variable region and a heavy chain variable region,
wherein the light chain variable region comprises the following CDRs: QSILYSSNHKN (SEQ ID NO:42), WASTRESGVP (SEQ ID NO:43), and HQYLSS (SEQ ID NO:44); and
wherein the heavy chain variable region comprises the following CDRs: GFSLSSYG (SEQ ID NO:45), IWRSGNT (SEQ ID NO:46), and AKNFRYDVGSWFAY (SEQ ID NO:47).
US Pat. No. 10,458,002

GREY GOLD ALLOY

1. A grey gold alloy, which is nickel-free, cobalt-free, iron-free, silver-free, zirconium-free, niobium-free, chromium-free, indium-free, gallium-free and manganese-free, comprising, expressed in weight percent, the following elements:75.0 to 76.5% of Au,
15 to 23% of Pd,
1 to 7% of Cu,
0 to 5% of at least one of the alloying elements Ir, Ru, B and Re,
the respective percentages of all the elements of the alloy adding up to 100%.
US Pat. No. 10,456,464

LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUG

NITTO DENKO CORPORATION, ...

1. A vaccine pharmaceutical composition for inducing humoral immunity, comprising:an infectious pathogen-derived antigen in an amount of 0.000001 to 50% by weight based on a total weight of the vaccine pharmaceutical composition; and
a humoral immunity induction-promoting composition comprising a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug, wherein the humoral immunity induction promoter is present in an amount of 0.001 to 10,000 parts by weight based on 1 part by weight of the antigen;
wherein the infectious pathogen is selected from adenovirus, herpesvirus, picornavirus, poxvirus, picornavirus, orthomyxovirus, paramyxovirus, parvovirus, togavirus, coronavirus, hepadnavirus, flavivirus, hepevirus, papillomavirus, calicivirus, rhabdovirus, filovirus, arenavirus, bunyavirus, reovirus, retrovirus, Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococci, Clostridium, Bacillus, Corynebacterium, Mycobacterium, Campyrobacter, Vibrio, Serratia, Providencia, Chromobacterium, Brucella, Yersinia, Haemophilus, Bordetella, and pathogens that cause chlamydia, candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, malaria, pneumocystis carinii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and Trypanosoma infection; and
wherein the thrombosis treatment drug is a thrombogenesis-suppressing compound that is at least one of an anticoagulant or an antiplatelet,
the anticoagulant being at least one selected from the group consisting of fondaparinux, rivaroxaban, apixaban, edoxaban, betrixaban, eribaxaban, ximelagatran, dabigatran, argatroban, hirudin, nafamostat, camostat, gabexate, and warfarin, and
the antiplatelet being at least one selected from the group consisting of abciximab, eptifibatide, and tirofiban.
US Pat. No. 10,457,747

METHOD FOR OBTAINING HIGH-YIELD, STABLE EXPRESSION CELL CLONES AND ANTIBODY MOLECULES OBTAINED THEREBY

BIOTECH PHARMACEUTICAL CO...

1. A method for obtaining stable producer cell clones from myeloma cell lines in protein-free medium producing recombinant antibodies for industrial purposes that comprise three stages:I. placing the myeloma cell lines into a protein-free, lipid-enriched-supplement medium and performing a stepwise reduction of the lipid-enriched supplement until the lipid-enriched supplement is removed,
wherein the stepwise reduction comprises the lipid-enriched-supplement first being in a concentration of about +3.5 g/L until Xv reaches a constant value, then the lipid-enriched-supplement being in a concentration of about +1 g/L until Xv reaches a constant value,
II. and then growing the cell lines, wherein the cell density is about 1.5 1.8×106 cells/ml, thereby producing myeloma cell lines adapted to protein-free medium,
III. placing the myeloma cell lines adapted to protein-free medium into a perfusion fermentation system, wherein the cell density is about 5-10×106 cells/ml, and
IV. selecting stable producer cell clones from cell lines at the end of fermentation of stage II.
US Pat. No. 10,456,465

COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1

Dana-Farber Cancer Instit...

1. A method for treating a human subject afflicted with a post-transplant lymphoproliferative disorder (PTLD) in which lymphocytes are infected with a virus, are overproduced, and overexpress wild-type galectin 1 (Gal1) comprising administering an anti-Gal1 monoclonal antibody or antigen-binding fragment thereof comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein CDR-H1 consists of residues 31-35 of SEQ ID NO: 7, CDR-H2 consists of residues 50-66 of SEQ ID NO: 7, CDR-H3 consists of residues 99-107 of SEQ ID NO: 7, CDR-L1 consists of residues 23-36 of SEQ ID NO: 9, CDR-L2 consists of residues 52-58 of SEQ ID NO: 9, and CDR-L3 consists of residues 91-99 of SEQ ID NO: 9.
US Pat. No. 10,457,748

SINGLE LINKER FABFV ANTIBODIES AND METHODS OF PRODUCING SAME

UCB BIOPHARMA SPRL, Brus...

1. A pharmaceutical composition comprising a purified monomeric form of a multi-specific antibody molecule and at least one excipient, said multi-specific antibody molecule consisting of three polypeptides,a) a polypeptide chain of formula (I):
(Vxx)nVx-Cx-X-V1,
b) a polypeptide chain of formula (II):
(Vyy)nVy-Cy, and
c) a polypeptide of formula (III):
V2,
wherein
Vx represents a variable domain,
Vxx represents a variable domain,
Cx represents a constant region consisting of CH1,
X represents a linker,
V1 represents a variable domain,
Vy represents a variable domain,
Vyy represents a variable domain,
Cy represents a constant region selected from a Ckappa or Clambda sequence,
V2 represents a variable domain,
n independently represents 0 or 1,
wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired, the variable domains Vx and Vy are paired to form a binding domain, the variable domains V1 and V2 are paired to form a binding domain, and a disulphide bond is present between V1 and V2, and wherein at least 90 percent of the antibody molecules in the composition are in monomeric form;
wherein the variable domain pair V1/V2 are linked by a disulfide bond between two engineered cysteine residues, one in V1 and one in V2; and
wherein the position of the pair of engineered cysteine residues is selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH100b and VL49, VH98 and VL46, VH101 and VL46, VH105 and VL43 and VH106 and VL57.
US Pat. No. 10,456,466

ANTI-VEGF ANTIBODY

Zhuhai Essex Bio-Pharmace...

1. An anti-VEGF antibody or fragment thereof, wherein the antibody or fragment thereof comprises a heavy chain variable region, wherein the heavy chain variable region comprises:CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively.
US Pat. No. 10,457,749

METHODS OF PURIFYING BISPECIFIC ANTIBODIES

NovImmune SA, Geneva (CH...

1. A method of purifying a bispecific antibody from a mixture of antibodies, the method comprising the steps of:(a) performing protein A chromatography on a biological sample to produce a mixed antibody composition comprising of (i) at least one bispecific antibody with a different specificity in each combining site and two copies of a single heavy chain polypeptide, a first light chain with a kappa constant region, and a second light chain with a lambda constant region (??-body); (ii) at least one monospecific antibody having two lambda light chains or portions thereof (? mono-Ab); and (iii) at least one monospecific antibody having two kappa light chains or portions thereof (? mono-Ab);
(b) contacting the mixed antibody composition with a separation means under conditions that allow for differential binding to the separation means by the ??-body as compared to the binding to the separation means by the ? mono-Ab and the ? mono-Ab, wherein the separation means comprises a combination of a hydrophobic interaction chromatography resin and a mix mode chromatography resin; and
(c) eluting the ??-body, the ? mono-Ab, and the ? mono-Ab from the separation means under conditions that allow for preferential detachment of the ??-body from the separation means as compared to detachment of ? mono-Ab and of the ? mono-Ab from the separation means.
US Pat. No. 10,458,005

HEAT-RESISTANT AND CORROSION-RESISTANT HIGH-CHROMIUM NICKEL-BASED ALLOY WITH SUPERIOR HOT FORGEABILITY

Hitachi Metals, Ltd., To...

1. A heat-resistant and corrosion-resistant high-Cr-containing Ni-based alloy suitable for hot forgeability, the alloy having a composition consisting of, by mass %,43.1% to 45.5% of Cr,
0.5% to 1.5% of Mo,
0.0001% to 0.0090% of Mg,
0.001% to 0.040% of N,
0.05% to 0.50% of Mn,
0.01% to 0.10% of Si,
0.05% to 1.00% of Fe,
0.01% to 1.00% of Co,
0.01% to 0.30% of Al,
0.04% to 0.3% of Ti,
0.0003% to 0.0900% of V,
0.0001% to 0.0100% of B,
0.001% to 0.050% of Zr,
optionally 0.001% to 0.020% of Cu,
optionally 0.001% to 0.100% of W,
optionally 0.0001% to less than 0.0020% of Ca,
optionally 0.001% to less than 0.100% of Nb, and
the balance of Ni with inevitable impurities.
US Pat. No. 10,457,750

THERMOSET FOAMS, AND METHOD FOR MANUFACTURING SAME FROM REDUCING SUGARS AND AMINES

SAINT-GOBAIN ISOVER, Cou...

1. A process for manufacturing a solid thermoset foam, comprising the following successive stages:(a) making available an expandable and thermosetting composition containing:
a first reactant chosen from reducing sugars,
a second reactant chosen from primary amines, primary amine acid addition salts, secondary amines, secondary amine acid addition salts, and ammonium salts of formula Rn?(NH4+)n where n is an integer at least equal to 1 and Rn? represents a residue of an organic or inorganic acid,
the expandable and thermosetting composition containing less than 50% by weight of water,
(b) introducing the expandable and thermosetting composition into a mold or applying the expandable and thermosetting composition on a support so as to form a film having a thickness at least equal to 1 mm,
(c) heating the expandable and thermosetting composition to a temperature at least equal to 140° C., so as to react the first reactant with the second reactant and to form, by polymerization and chemical foaming, a block of solid thermoset foam.
US Pat. No. 10,457,751

METHOD FOR PRODUCING BROMINATED AND HALOHYDRATED POLYMERS

DOW GLOBAL TECHNOLOGIES L...

1. A process for preparing a brominated and halohydrated polymer of at least one conjugated diene, comprising (a) reacting a starting polymer of at least one conjugated diene with a quaternary ammonium tribromide, quaternary phosphonium tribromide compound or both a quaternary ammonium tribromide and a quaternary phosphonium tribromide to brominate 50% to 98% of the conjugated diene repeating units in the starting polymer to form a partially brominated polymer and then (b) reacting the partially brominated polymer with an N-haloimide compound in the presence of water and a water-miscible solvent system for the partially brominated polymer to halohydrate at least a portion of the remaining conjugated diene repeating units and produce a brominated and halohydrated polymer.
US Pat. No. 10,458,007

QUENCH AND TEMPER CORROSION RESISTANT STEEL ALLOY

CRS HOLDINGS, INC., Wilm...


and the balance is iron and impurities wherein phosphorus is restricted to not more than about 0.005%, sulfur is restricted to not more than about 0.001%, and nitrogen is restricted to not more than about 0.03%.
US Pat. No. 10,457,752

SILANE FUNCTIONALIZED POLY (FARNESENE) AND RUBBER COMPOUND COMPRISING THE SAME

FINA TECHNOLOGY, INC., H...

1. A curable rubber composition comprising:a high molecular weight diene elastomer having a number average molecular weight Mn above 80,000 Da;
a silica;
a carbon black; and
a farnesene polymer produced via living anionic polymerization of at least one farnesene monomer, the farnesene polymer having at least one terminal end modified with at least one silane group, wherein the farnesene polymer has a number average molecular weight of 1,000 g/mol to 100,000 g/mol, a silane functionality of two or less and a glass transition temperature of equal to or less than ?40° C., wherein the farnesene polymer is produced by process i) or process ii):
i) a process comprising polymerizing farnesene monomers to obtain a living farnesene polymer having one or more living ends and capping the living ends of the living farnesene polymer with a silane ester;
ii) a process comprising polymerizing farnesene monomers to obtain a living farnesene polymer, modifying at least one terminal end of the living farnesene polymer by reacting the living farnesene polymer with an alkylene oxide followed by a proton source to produce a hydroxyl-terminated farnesene polymer having at least one terminal hydroxyl group, and modifying at least one terminal hydroxyl group of the hydroxyl-terminated farnesene polymer by converting the at least one terminal hydroxyl group to a silane group.
US Pat. No. 10,459,290

OPTICAL FILM, POLARIZING PLATE, AND IMAGE DISPLAY DEVICE

FUJIFILM Corporation, To...

1. An optical film containing a cellulose acylate film wherein:the cellulose acylate film contains a cellulose acylate and an aromatic ester oligomer having a repeating unit derived from a dicarboxylic acid and a repeating unit derived from a diol,
the cellulose acylate film has a thickness of from 15 to 35 ?m,
the repeating unit derived from a dicarboxylic acid has a ratio m/n of from 0/10 to 3/7,
wherein m represents a molar proportion of a repeating unit derived from an aliphatic dicarboxylic acid, and n represents a molar proportion of a repeating unit derived from an aromatic dicarboxylic acid, and
the cellulose acylate film satisfies the following expression (1):
|Rth(590)|?50 nm  (1)
wherein Rth(590) represents a retardation in a thickness direction at a wavelength of 590 nm,
wherein a proportion of a repeating unit derived from ortho-phthalic acid in the repeating unit derived from the dicarboxylic acid contained in the aromatic ester oligomer is 70% by mol or more, and
wherein the Knoop hardness of the optical film is 240 or more N/mm2.
US Pat. No. 10,456,470

DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA

Genentech, Inc., South S...

1. A method of treating a patient having a proneural subtype glioblastoma who is likely to respond to treatment with an anti-VEGF antibody, the method comprising:(a) detecting expression of at least one of the genes set forth in Table 1, 2, or 3 in a biological sample obtained from the patient prior to administration of the anti-VEGF antibody to the patient;
(b) comparing the expression level of the at least one gene to a reference expression level of the at least one gene, wherein a change in the level of expression of the at least one gene in the patient sample relative to the reference expression level identifies the patient as one who has a glioblastoma of the proneural subtype and is likely to respond to treatment with the anti-VEGF antibody; and
(c) administering an effective amount of the anti-VEGF antibody to the patient identified as likely to respond to treatment with the anti-VEGF antibody.
US Pat. No. 10,458,009

FREE-MACHINING WROUGHT ALUMINIUM ALLOY PRODUCT AND MANUFACTURING PROCESS THEREOF

CONSTELLIUM EXTRUSIONS DE...

1. A wrought aluminium alloy product having the following chemical composition, expressed in weight % (wt. %):1.3%?Si?12%,
1.35%?Fe?1.8%wherein the total Fe+Si content is higher than 3.4%;0.15%?Cu?1%;
0.6%?Mg?3%;
optionally, one or more of the following elements:
Mn?1%;
Cr?0.25%;
Ni?3%;
Zn?1%;
Ti?0.1%;
Bi?0.7%;
In?0.7%;
Sn?0.7%
other elements <0.05% each and 0.15% in total;wherein the total Fe+Mn content is lower than 1.9 wt %and the balance aluminium,and wherein ultimate tensile strength of the wrought aluminum alloy product is higher than 400 Mpa.
US Pat. No. 10,460,827

IDENTIFICATION OF THERAPEUTIC TARGETS FOR COMPUTER-BASED DESIGN OF DRUGS AGAINST BACTERIA CONTAINING THE PILT PROTEIN

EMPRESA BRASILEIRA DE PES...

1. A method for identifying drug candidates that inhibit motility of PilT-expressing Xylella fastidiosa, comprising:(a) selecting at least one interface-forming residue from a PilT protein from a PilT-expressing Xylella fastidiosa as a therapeutic target site, wherein said at least one interface-forming residue is selected from the group consisting of residue D184, E89, K187, E258, E74, K235, K249, R35, R90, D33, E248, R36, H152, E336, K58, R212, R335 and E65 from Xylella fastidiosa PilT; and
(b) identifying at least one drug candidate predicted to bind to said therapeutic target site, wherein said identifying comprises one or more of de novo drug design and virtual screening.
US Pat. No. 10,456,471

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

AXSOME THERAPEUTICS, INC....

1. A method of improving dissolution of meloxicam in a stomach of a human being, comprising orally administering a solid dosage form comprising a bicarbonate and a complex of meloxicam with a cyclodextrin to the human being, wherein the solid dosage form contains 400 mg to 800 mg of the bicarbonate, wherein, at a designated time, the dissolution of meloxicam for the solid dosage form is improved as compared with a reference dosage form that: 1) contains the same amount of meloxicam; 2) contains the same amount of the cyclodextrin; and 3) does not contain the bicarbonate, wherein the rate of dissolution of meloxicam of the solid dosage form or the reference dosage form is determined by a dissolution test, wherein the dissolution test is: adding the dosage form or the reference dosage form to 500 mL of a 0.01 N HCl aqueous solution, stirring at 75 revolutions per minute (RPM) with a USP paddle apparatus II at 37° C., and determining the amount of meloxicam dissolved in the 0.01 N HCl aqueous solution at the designated time.
US Pat. No. 10,460,828

METHOD OF NUCLEIC ACID FRAGMENT DETECTION

Lifeos Genomics Corporati...

1. A method of nucleic acid fragment detection, the method comprising:capturing a target nucleic acid fragment by an oligonucleotide probe to form a section of hybridised double strand, the oligonucleotide probe having an identification sequence and a reproducible sequence, the identification sequence being complementary to the target nucleic acid fragment;
removing the hybridised double strand section to expose the reproducible sequence of the oligonucleotide probe, wherein the removing the hybridised double strand comprises: cleaving the hybridized double strand off the oligonucleotide probe by duplex specific nuclease (DSN);
producing repeats of the reproducible sequence; and
labelling the repeats of the reproducible sequence by a detection probe.
US Pat. No. 10,456,472

PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS

EMISPHERE TECHNOLOGIES, I...

1. A composition comprising:(A) a biologically active agent; and
(B) a delivery agent compound selected from
3-(3-phenoxyphenyl)propanoic acid,
4-(4-ethylphenyl)butanoic acid,
5-(4-ethylphenyl)pentanoic acid,
and pharmaceutically acceptable salts thereof.
US Pat. No. 10,460,830

COMPUTER-BASED SYSTEMS AND METHODS FOR ANALYZING GENOMES BASED ON DISCRETE DATA STRUCTURES CORRESPONDING TO GENETIC VARIANTS THEREIN

GENOMONCOLOGY, LLC, Clev...

1. A computer-based method for analyzing genetic variants within a plurality of genomes, the method comprising:submitting a query term to a database storing a plurality of discrete data structures within a memory, each data structure uniquely corresponding to only one of the genetic variants present within the plurality of genomes, each data structure comprising a first data field comprising a unique alphanumeric identifier for the corresponding genetic variant, a second data field comprising a unique alphanumeric identifier for a genome in which the corresponding genetic variant is present, and a third data field comprising an alphanumeric representation of a nucleic acid characteristic, the query term comprising a unique alphanumeric identifier for at least one genome of the plurality of genomes, an identification of a nucleic acid characteristic, and an operation to be performed on that genome;
searching the second and third data fields of the plurality of data structures stored in the database for unique alphanumeric identifiers that match the query term and satisfy the operation; and
generating an output representing the result of performing the search;
wherein the third data field is generated by:
obtaining a genome mask comprising a plurality of chromosome masks, each chromosome mask corresponding to a chromosome and comprising an array of bits, each bit corresponding to a base pair position in the corresponding chromosome, wherein only bits corresponding to a position of the nucleic acid characteristic include a flag;
determining whether a bit within the genome mask that corresponds to the chromosome and position of the corresponding genetic variant includes a flag; and
if the bit is determined to include a flag, submitting a query to the curated data source information about the nucleic acid characteristic at the chromosome and position corresponding to that bit, and storing the query result in the third data field.
US Pat. No. 10,456,474

CYCLOSPORIN COMPOSITIONS

Saint Regis Mohawk Tribe,...

1. A method of treating keratoconjunctivitis sicca, the method comprising administering a composition comprising about 0.001% cyclosporin A, a surfactant, and an oil selected from the group consisting of almond oil, corn oil, arachis oil, cottonseed oil, safflower oil, rosemary oil, peanut oil, peppermint oil, sunflower oil, and eucalyptus oil to a patient in need thereof, wherein said composition is an ophthalmically acceptable emulsion.
US Pat. No. 10,456,475

CELL PENETRATING PROTEIN ADAPTOR MOLECULES AND THEIR APPLICATION IN RESEARCH AND MEDICINE

Kennsaw State University ...

1. A biological complex for translocating a cargo into a cell, the complex comprisinga. a cell penetrating peptide (CPP) fused to an adaptor by a covalent linkage, and
b. the cargo, the cargo containing an adaptor binding molecule;
wherein the adaptor binding molecule reversibly binds to the adaptor;
wherein the adaptor is calmodulin and the adaptor binding molecule is a calmodulin binding peptide; and
wherein the CPP is selected from the group consisting of TAT, Penetratin, Transportan, Dat, VP-22, MPG, Pep-1, MAP, SAP, PPTG1, oligoarginine, hCT (9-32), SynB, and Pvec.
US Pat. No. 10,460,832

EXACT HAPLOTYPE RECONSTRUCTION OF F2 POPULATIONS

International Business Ma...

1. A system for generating an agglomerate data structure that reduces computation time of one or more information processing systems when reconstructing haplotypes from genotype data in a model-free setting, the system comprising:a memory;
a processor communicatively to the memory; and
a reconstruction circuit communicatively coupled to the memory and processor, the reconstruction circuit:
electronically communicating with at least one external information processing system;
electronically receiving, based on electronically communicating with the at least one external information processing system, a set of progeny genotype data, the set of progeny genotype data comprising n progenies encoded with m biallelic genetic markers, where each of the n progenies are full siblings, wherein each of the m biallelic genetic markers comprises two values, and wherein a combination of each of the m biallelic genetic markers associated with a progeny represents a genotype sequence of the progeny comprising at least a chromosome segment;
constructing, by based on the set of progeny genotype data, an agglomerate data structure comprising a collection of sets of haplotype sequences characterizing the n progenies in terms of first and second sets of parent haplotypes, wherein each set of haplotype sequences comprises a number of observable crossovers equal to the total minimum number of observable crossovers in the n progenies;
reducing computation time of the one or more information processing systems when reconstructing haplotypes from genotype data in a model-free setting by constructing the agglomerate data structure in linear time, wherein constructing the agglomerate data structure in linear time comprises:
electronically transforming the set of progeny genotype data into a data structure, the data structure encoding the set of progeny genotype data where the encoding represents each of n progenies in the set of progeny genotype data as one row in a plurality of rows of the data structure and represents each of m biallelic genetic markers in the set of progeny genotype data as one column in a plurality of columns of the data, wherein the encoding further orders the plurality of columns corresponding to an order of the m biallelic genetic markers;
electronically accessing the set of progeny genotype data within the data structure;
identifying, based on electronically accessing the set of progeny genotype data, a first set of parent haplotypes associated with a first parent of the n progenies and a second set of parent haplotypes associated with a second parent of the n progenies, the identifying comprising
splitting the data structure into a first parental data structure and a second parental data structure by transforming a set of data representing genetic contributions for each of a first parent and a second parent of the n progenies and inferring any missing genotype data for one or more of at least one of the n progenies parents, the first parent, or the second parent wherein the transforming comprises utilizing a set of monotonic state transitions that systematically transform the set of data into the first parental data structure and the second parental data structure each comprising different data than the set of data, wherein the first parental data structure encodes haplotypes of a first parent of the n progenies and the second parental data structure encodes haplotypes of a second parent of the n progenies, where the first set of parent haplotypes is identified from the first parental data structure and the second set of parent haplotypes is identified from the second parental data structure;
determining a total minimum number of observable crossovers in the n progenies based on data within the first parental data structure and a second parental data structure;
constructing, based on the set of progeny genotype data and the first and second sets of parent haplotypes, the agglomerate data structure comprising a collection of sets of haplotype sequences characterizing the n progenies in terms of the first and second sets of parent haplotypes, wherein each set of haplotype sequences comprises a number of observable crossovers equal to the total minimum number of observable crossovers in the n progenies; and
programming a processor of at least one information processing system utilizing the collection of sets of haplotype sequences from the agglomerate data structure to at least
analyze statistical trends regarding haplotype distribution along chromosomes to observe biases, and determine a specific form of a gene that is associated with disease susceptibility.
US Pat. No. 10,457,759

CO-DELIVERY OF CHOLESTEROL LOWERING DRUGS AND NUTRACEUTICALS

International Business Ma...

1. A loaded star polymer, comprising:a star polymer macromolecule, the star polymer comprising a crosslinked hydrophobic core covalently linked to a plurality of block polymer arms emanating from the core, wherein each arm comprises i) a hydrophobic first block linked to the core and ii) a peripheral second block linked to the first block, the second block comprising a repeat unit containing a sidechain tertiary amine group capable of undergoing protonation to form a hydrophilic tertiary ammonium ion;
a cholesterol lowering drug selected from the group consisting of simvastatin, lovastatin, atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, and combinations thereof; and
a nutraceutical selected from the group consisting of ubiquinone (coenzyme Q10), menadione, duroquinone, idebenone, decylubiquinone, and combinations thereof; wherein
the star polymer, the cholesterol lowering drug, and the nutraceutical are bound together by non-covalent interactions, and
the loaded star polymer is water-dispersible.
US Pat. No. 10,456,477

OLIGOLACTIC ACID CONJUGATES AND MICELLES WITH ENHANCED ANTICANCER EFFICACY

WISCONSIN ALUMNI RESEARCH...

1. An oligolactic acid conjugate selected from the group consisting of a 7-oligolactic acid conjugate of paclitaxel or a paclitaxel derivative, a 40-oligolactic acid conjugate of rapamycin or a rapamycin derivative, and a 2?-oligolactic acid conjugate of selumetinib or a selumetinib derivative;wherein:the oligolactic acid comprises 2 to 24 lactic acid subunits;
the 7-oligolactic acid is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative;
the 40-oligolactic acid is attached through an ester linkage to the oxygen of the 40-hydroxyl of the rapamycin or rapamycin derivative; and
the 2?-oligolactic acid is attached through an ester linkage to the oxygen of the 2?-hydroxyl of the selumetinib or selumetinib derivative.
US Pat. No. 10,456,478

DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO

1. A method of delivering a therapeutic nucleic acid to a subject in need thereof comprising administering to the subject a therapeutically effective amount of a dually derivatized (DD) chitosan nucleic acid polyplex, wherein said DD chitosan nucleic acid polyplex comprises a chitosan-derivative nanoparticle comprising chitosan coupled with gluconic acid and arginine and said therapeutic nucleic acid.
US Pat. No. 10,456,480

TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES

Mayo Foundation for Medic...

1. A method for reducing elevated intraocular pressure, said method comprising administering a viral vector to an eye of a mammal under conditions effective to reduce intraocular pressure of said eye, wherein said viral vector comprises a nucleic acid encoding a cyclooxygenase-2 polypeptide.
US Pat. No. 10,457,763

AQUEOUS POLYMER EMULSION

DSM IP ASSETS B.V., Heer...

1. A coating formed of a dried residue of a coating or paint composition comprised of an aqueous polymer emulsion comprising at least 70 wt. % of a vinyl copolymer (A) relative to the total weight amount of polymers present in the emulsion, wherein the vinyl copolymer (A) comprises:(I) from 25 to 55 wt. % of 2-octyl acrylate monomer;
(II) from 20 to 65 wt. % of dimethyl itaconate monomer; and
(III) from 0 to 55 wt. % of ethylenically unsaturated monomer other than the monomers (I) and (II), wherein
the summed amount of monomers (I), (II) and (III) is 100 wt. %, and wherein the monomer (III) comprises:
(IIIa) from 0.1 to 15 wt. % of carboxylic acid functional olefinically unsaturated monomer;
(IIIb) from 0 to 5 wt. % of olefinically unsaturated crosslinkable monomer, different from (IIIa), (IIIc) and (IIId);
(IIIc) from 0 to 5 wt. % of olefinically unsaturated wet adhesion promotor monomer, different from (IIIa), (IIIb) and (IIId);
(IIId) from 0 to 54.9 wt. % of olefinically unsaturated monomer, different from (IIIa), (IIIb) and (IIIc); wherein
wherein the amounts of (IIIa), (IIIb), (IIIc) and (IIId) are given relative to the total amount of (I), (II) and (III), and wherein
the coating exhibits improved water resistance as compared to an identical coating where a 2-ethylhexyl acrylate monomer is employed instead of the 2-octyl acrylate monomer.
US Pat. No. 10,457,764

MODIFIED HYDROCARBON RESIN AND HOT MELT ADHESIVE COMPOSITION

ZEON CORPORATION, Chiyod...

1. A modified hydrocarbon resin obtained by hydrogenating a hydrocarbon resin comprising:a 1,3-pentadiene monomeric unit of 20 mass % to 70 mass %,
a C4-6 alicyclic monoolefin monomeric unit of 10 mass % to 35 mass %,
a C4-8 acyclic monoolefin monomeric unit of 5 mass % to 30 mass %,
an alicyclic diolefin monomeric unit of 0 mass % to 1 mass %, and
an aromatic monoolefin monomeric unit of 0 mass % to 40 mass %,
the modified hydrocarbon resin being characterized in that:a degree of hydrogenation of the olefins is within a range of 30% to 80%;a degree of hydrogenation of the aromatic rings, if an aromatic monomeric unit is included, is within a range of 5% to 20%;
a weight average molecular weight (Mw) is within a range of 1,000 to 4,000;
a Z-average molecular weight (Mz) is within a range of 2,500 to 10,000;
a ratio (Mz/Mw) of the Z-average molecular weight to the weight-average molecular weight is within a range of 1.5 to 2.5;
a Gardner color scale of a toluene solution of 50 mass % is 2 or lower; and
a difference between pre-hydrogenation and post-hydrogenation mixed aniline point (MMAP) is 5° C. or less.
US Pat. No. 10,456,738

METHOD AND APPARATUS FOR SEPARATING ONE OR MORE COMPONENTS FROM A COMPOSITION

Dow Silicones Corporation...

1. A method of separating one or more components from a feed composition, the method comprising:contacting at least some of a first component of a feed composition comprising the first component with an absorbent fluid comprising an organosilicon fluid comprising an organosilicon compound having the formula:
R13SiO(R12SiO)?(R1R2SiO)?SiR13,  (a)
R4R32SiO(R32SiO)?(R3R4SiO)?SiR32R4, or  (b)
(R1R4R5SiO1/2)w(R1R4SiO2/2)x(R4SiO3/2)y(SiO4/2)z,  (c)wherein,0?w<0.95;
0?x<1;
0?y<1;
0?z<0.95;
w+x+y+z?1;
? has an average value of 0 to 2000;
? has an average value of 2 to 2000;
? has an average value of 0 to 2000;
? has an average value of 0 to 2000;
each R1 and R3 is independently at each occurrence a monovalent acrylic group, alkyl, a halogenated hydrocarbon group, alkenyl, alkynyl, aryl, or cyanoalkyl;
each R2 is independently at each occurrence a hydroxy group, an ether group, an acrylate group, a methacrylate group, an acrylamide group, a methacrylamide group, a polyether group, a (C1-10)alkyl group having at least one of a hydroxy group, an ether group, an acrylate group, a methacrylate group, an acrylamide group, a methacrylamide group, or a polyether group substituted thereon, or R1;
each R4 is independently at each occurrence a hydroxy group, an ether group, an acrylate group, a methacrylate group, an acrylamide group, a methacrylamide group, a polyether group, a (C1-10)alkyl group having at least one of a hydroxy group, an ether group, an acrylate group, a methacrylate group, an acrylamide group, a methacrylamide group, or a polyether group substituted thereon, or R3;
R5 is R1 or R4;
to provide a contacted composition and a used absorbent fluid comprising at least some of the first component contacted with the absorbent fluid; and wherein the organosilicon compound is:
i) combined with at least one of the following to form a mixture, and/or
ii) is a copolymer with at least one of the following:gelatin, methylcellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, polyethylene oxide, polyacrylamides, poly(n-isopropylacrylamide), poly(N,N-dimethyl acrylamide), polyacrylic acid, polymethacrylic acid, salts of polyacrylic acid, salts of polymethacrylic acid, poly(2-hydroxyethyl methacrylate), polylactic acid, polyglycolic acid, polyvinylalcohol, polyanhydrides, collagen, poly(hyaluronic acid), hyaluronic acid-containing polymers and copolymers, polypeptides, maltose, dextrose, glucose, xylitol, saccharin, disaccharides, polysaccharides, dextran, dextran sulfate, chitosan, chitin, agarose gels, fibrin gels, soy-derived hydrogels, poly(sodium alginate), and combinations thereof.
US Pat. No. 10,458,021

TREATMENT SOLUTION FOR CHROMIUM-FREE TENSION COATING, METHOD FOR FORMING CHROMIUM-FREE TENSION COATING, AND GRAIN ORIENTED ELECTRICAL STEEL SHEET WITH CHROMIUM-FREE TENSION COATING

JFE STEEL CORPORATION, T...

1. A grain oriented electrical steel sheet with chromium-free tension coating obtained by applying a treatment solution on a surface of a grain oriented electrical steel sheet subjected to final annealing and performing baking treatment at a temperature of 800° C. or higher and 1000° C. or lower for 10 seconds to 300 seconds, wherein the treatment solution comprises:one or more of a Mg phosphate, Ca phosphate, Ba phosphate, Sr phosphate, Zn phosphate, Al phosphate, and Mn phosphate;
colloidal silica in an amount of 50 parts by mass to 120 parts by mass per 100 parts by mass of the one or more phosphates in terms of solid content of SiO2;
Ti source in an amount of 30 parts by mass to 50 parts by mass per 100 parts by mass of the one or more phosphates in terms of solid content of TiO2; and
H3PO4, and
the number of moles of metallic elements in the one or more phosphates and the number of moles of phosphorus in the treatment solution satisfy the relation of formula (1)
0.20?([Mg]+[Ca]+[Ba]+[Sr]+[Zn]+[Mn]+1.5[Al])/[P]?0.45  (1)
where each symbol of element shown in square brackets represents the number of moles of the element contained in the treatment solution.
US Pat. No. 10,456,483

GAS-ENCAPSULATED ACOUSTICALLY RESPONSIVE STABILIZED MICROBUBBLES AND METHODS FOR TREATING CARDIOVASCULAR DISEASE

University of Cincinnati,...

1. An acoustically responsive microbubble comprising:a phospholipid monolayer shell comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG 2000),
an encapsulated bioactive gas selected from the group consisting of nitric oxide, xenon gas, and hydrogen sulfide, and
an encapsulated perfluorocarbon gas of the formula CxFy,
wherein X=3 and Y=8, and wherein a volume ratio of bioactive gas to CxFy is from about 10:1 to about 1:10.
US Pat. No. 10,457,766

LONG-CHAIN BRANCHED POLYPROPYLENE FOR FILM APPLICATION

BOREALIS AG, Vienna (AT)...

1. A process for producing a long-chain branched propylene homopolymer or copolymer (b-PP), wherein the process comprises:producing a propylene homopolymer or copolymer having a comonomer content in the copolymer selected from ethylene, C4-C20-alpha olefin and any combination thereof, with a comonomer content in the range of 0.1 to 7.0 wt %, in a polymerization process in the presence of a catalyst system comprising:
(a) a Ziegler-Natta based catalyst with a transition metal of Group 4 to 6 (TM), the catalyst containing an internal donor,
(b) optionally a co-catalyst (Co),
(c) optionally an external donor (ED) and wherein if present, the co-catalyst (Co) to external donor (ED) molar ratio [Co/ED] is in the range of 3.0 to 45.0 mol/mol and wherein the co-catalyst (Co) to transition metal of Group 4 to 6 (TM) molar ratio [Co/TM] is in the range of 40.0 to 500 mol/mol;
wherein the resulting propylene homopolymer or copolymer powder has:
(a) a porosity of more than 8.0%,
(b) a median particle size d50 in the range of 150 to 1500 ?m, and
(c) a top-cut particle size d95 in the range of 500 to 400 ?m,
wherein the internal donor comprised in the Ziegler-Natta catalyst (a) is a non-phthalic compound; and
mixing said propylene homopolymer or copolymer with a thermally decomposing free radical-forming agent and optionally with at least one functionally unsaturated compound at a temperature of 20 to 100° C. for at least 2 minutes to form a pre-mixed material and melt mixing the premixed material in a melt mixing device at a barrel temperature in the range of 180 to 300° C. to obtain said long-chain branched propylene homopolymer or copolymer (b-PP), wherein the long-chain branched propylene homopolymer or copolymer (b-PP) has:
(a) a comonomer in the copolymer selected from ethylene, C4-C20-alpha olefin and any combination thereof and a comonomer content in the range of 0.1 to 7.0 wt %,
(b) the melt flow rate MFR2 (230° C.) of the b-PP is in the range of 6.5 to 25.0 g/10 min as measured according to ISO 1133,
(c) the F30 melt strength of the b-PP is in the range of 5.0 to 12.0 cN wherein the F30 melt strength of the b-PP is measured according to ISO 16790:2005,
(d) the xylene hot insoluble (XHU) fraction of the b-PP is less than 0.08 wt % as measured according to EN 579, and
(e) the b-PP is free of phthalic compound.
US Pat. No. 10,457,767

METHOD OF PREPARING A POLYCARBODIIMIDE POLYMER AND POLYCARBODIIMIDE POLYMER PREPARED THEREBY

BASF SE, Ludwigshafen am...

1. A method of producing a polycarbodiimide polymer, said method comprising the steps of:preparing a precursor compound from a monofunctional isocyanate compound at a desired temperature such that the precursor compound is heated at the desired temperature upon formation;
combining the precursor compound, a diisocyanate compound, and a carbodiimidization catalyst to form a reaction mixture; and
heating the reaction mixture for a first period of time at a first temperature, thereby reacting the precursor compound and the diisocyanate compound in the presence of the carbodiimidization catalyst to produce the polycarbodiimide polymer,
wherein the precursor compound contains a single carbodiimide bond, and
wherein the monofunctional isocyanate is synthesized by reaction of a difunctional isocyanate with a monofunctional alcohol, a monofunctional thiol, or a monofunctional amine.
US Pat. No. 10,457,768

MODIFIED POLYCARBODIIMIDE COMPOUND, CURING AGENT, AND THERMOSETTING RESIN COMPOSITION

NISSHINBO CHEMICAL INC., ...

1. A modified polycarbodiimide compound obtained by modifying a polycarbodiimide compound derived from a diisocyanate compound with at least one aliphatic amine selected from the group consisting of diethylamine, methylisopropylamine, tert-butylethylamine, di-sec-butylamine, 2-methylpiperidine and 2,6-dimethylpiperidine.
US Pat. No. 10,456,742

AQUEOUS LIME SLURRY, PREPARATION PROCESS AND USES

COATEX, Genay (FR)

1. An aqueous slurry of calcium hydroxide comprising water, calcium hydroxide, and a copolymer, said slurry having a dry content of at least 40% by weight, the viscosity of said aqueous slurry as measured by a Brookfield DVIII viscometer at 10 RPM being between 25 and 1,000 mPa·s at 20° C.,wherein said copolymer consists:
of methacrylic acid monomers and/or any of its salts,
optionally of acrylic acid monomers and/or any of its salts,
of one or more monomers with the formula (I):
R—X—R?  (I)
where:
R represents a polymerizable unsaturated group,
R? represents hydrogen or an alkyl group with from 1 to 4 carbon atoms,
X represents a structure with n unit(s) of ethylene oxide EO and m unit(s) of propylene oxide PO, arranged randomly or regularly, and
m and n are independent non-zero integers and are between 1 and 150, and wherein said slurry is prepared by a process comprising:
agitating a mixture of the water and the copolymer to form an aqueous solution;
adding the calcium hydroxide in powdered form to said aqueous solution and agitating to provide an initial slurry;
applying a homogeneous shear level greater than 50,000 s?1 to the initial slurry; and
optionally, while applying said shear level to said initial slurry, adding more copolymer and/or more powdered calcium hydroxide to said initial slurry.
US Pat. No. 10,457,771

BIOBASED HYDROXYL OR CARBOXYL POLYESTER RESINS

Arkema France, Colombes ...

1. A polyester resin having a linear or branched structure and free of unsaturated fatty acids, which is hydroxylated or carboxylated, optionally hydroxylated and carboxylated, which is derived from:a) an acid component a) comprising:
a1) at least one C4 to C6 polycarboxylic acid or anhydride,
a2) at least one C8 to C54 polycarboxylic acid or anhydride, wherein said polycarboxylic acid a2) is biobased and chosen from the group consisting of azelaic acid (C9), sebacic acid (C10), undecanedioic acid, dodecanedioic acid, and respectively C36 and C54 fatty acid dimers and trimers,
a3) optionally, at least one C2 to C22 saturated monoacid, which can optionally bear a hydroxyl group,
wherein the a1/a2 molar ratio ranges from 2 to 8,
b) an alcohol component b) comprising:
b1) at least one biobased polyol having a functionality fb1 of at least 2, bearing a 1,4:3,6-dianhydrohexitol unit,
and at least one of the following two polyols b2) and b3):
b2) at least one polyol different than b1) and having a functionality fb2 of at least 2, wherein said polyol b2) is biobased and is chosen from the group consisting of 1,3-propylenediol, 1,2-propylenediol, 1,4-butanediol, and diols derived from saturated fatty acids,
b3) at least one polyol different than b1) and than b2) having a functionality fb3 of at least 3;
wherein at least 50% by weight of said resin is biobased, the polyester resin having a carboxyl functionality corresponding to an acid number of less than 20 mg KOH/g and an OH functionality corresponding to an OH number ranging from 10 to 200 mg KOH/g.
US Pat. No. 10,461,358

RECHARGEABLE LITHIUM BATTERY

Samsung SDI Co., Ltd., Y...

1. A rechargeable lithium battery comprising:a positive electrode;
a negative electrode;
a separator between the positive electrode and the negative electrode;
a polymer layer on the separator, the polymer layer comprising polyvinylidene fluoride, the polyvinylidene fluoride loaded at a loading level of 1.5 to 2.5 g/m2; and
an electrolyte impregnating the separator, the electrolyte comprising a carbonate-based solvent and an alkyl propionate in a volume ratio of 4:6 to 5:5, the alkyl propionate comprising a compound selected from the group consisting of methyl propionate, ethyl propionate, and a combination thereof,
wherein the carbonate-based solvent comprises a cyclic carbonate-based solvent and a linear carbonate-based solvent in a volume ratio of 4:1 to 3:2, and the linear carbonate-based solvent is one or more selected from the group consisting of dimethyl carbonate, diethyl carbonate, dipropyl carbonate, methylpropyl carbonate, ethylpropyl carbonate, methylethyl carbonate, ethylmethyl carbonate and butylene carbonate.
US Pat. No. 10,456,746

SELECTIVE CATALYTIC REDUCTION FILTER FOR REDUCING NITROUS OXIDE FORMATION AND METHODS OF USING THE SAME

GM GLOBAL TECHNOLOGY OPER...

1. A selective catalytic reduction filter (SCRF) comprising:a wall-flow substrate defining inlet channels for receiving exhaust gas and outlet channels through which the exhaust gas exits, wherein the inlet channels and the outlet channels are connected to one another through porous walls of the inlet and outlet channels;
a first selective catalytic reduction (SCR) catalyst zone present in the inlet channels, wherein the first SCR catalyst zone has a first SCR catalyst loading and comprises a first SCR catalyst coating comprising an iron-exchanged zeolite; and
a second SCR catalyst zone present in the outlet channels, wherein the second SCR catalyst zone has a second SCR catalyst loading and comprises a second SCR catalyst coating comprising a copper-exchanged zeolite;
wherein the combined first SCR catalyst loading and the second SCR catalyst loading is less than or equal to about 200 g/l.
US Pat. No. 10,457,773

METHOD OF PREPARING POLYALKYLENE CARBONATE RESIN

LG Chem, Ltd., Seoul (KR...

1. A method of preparing a polyalkylene carbonate resin, the method comprising the sequential steps of:preparing a reaction mixture comprising polyalkylene carbonate, a catalyst residue, unreacted residual monomers, a chlorinated solvent, and alkylene carbonate-comprising by-products by polymerizing monomers comprising carbon dioxide and an epoxide compound in the presence of the catalyst and the chlorinated solvent;
recovering residual monomers from the reaction mixture;
removing the by-products from the reaction mixture, from which the residual monomers have been removed, by using 200 parts by weight to 1000 parts by weight of water with respect to 100 parts by weight of the monomers;
removing the catalyst residue from the reaction mixture, from which the residual monomers and the by-products have been removed, by using a filter having a pore size of less than 50 um; and
removing the chlorinated solvent from the reaction mixture, from which the residual monomers and the catalyst residue have been removed.
US Pat. No. 10,456,235

EMBOLIZATION PARTICULATES FOR OCCLUDING A BLOOD VESSEL

ACCURATE MEDICAL THERAPEU...

1. Embolization particulates suitable for occluding a blood vessel, the embolization particulates comprising:a plurality of embolization beads, each of said embolization beads comprises: a plurality of outwardly protruding portions, wherein, upon a first one and a second one of said embolization beads accumulating against a boundary of the blood vessel, said protruding portions of said first embolization bead are configured to intermesh with said protruding portions of said second embolization bead, so as to occlude the blood vessel;
wherein said embolization beads are formed with a tetrapod shape or a tetrahedron shape; and
wherein the embolization beads are configured to resist aggregation prior to reaching the blood vessel, and to aggregate within the blood vessel once delivered thereto.
US Pat. No. 10,458,286

COMPOSITIONS COMPRISING TETRAFLUOROPROPENE AND TETRAFLUOROETHANE; THEIR USE IN POWER CYCLES; AND POWER CYCLE APPARATUS

THE CHEMOURS COMPANY FC, ...

1. A method for converting heat from a heat source to mechanical energy in an organic Rankine apparatus, comprising heating a working fluid consisting essentially of E-1,3,3,3-tetrafluoropropene, 1,1,1,2-tetrafluoroethane, and 1,1,2,2-tetrafluoroethane, using heat supplied from the heat source; and expanding the heated working fluid to lower the pressure of the working fluid and generate mechanical energy as the pressure of the working fluid is lowered.
US Pat. No. 10,461,104

FRICTION MATERIAL

AKEBONO BRAKE INDUSTRY CO...

1. A friction material for a brake pad of a disk brake, comprising:potassium titanate having a plurality of protrudent shapes in an amount of 10-20% by volume of the friction material;
an abrasive material having a Moh's hardness of 7 or higher in an amount of 6-10% by volume of the friction material, wherein the abrasive material having a Moh's hardness of 7 or higher includes stabilized zirconia and zirconium silicate; and
an elastomer-modified phenolic resin in an amount of 20-30% by volume of the friction material, wherein the elastomer-modified phenolic resin includes silicone-rubber-modified phenolic resin in an amount of 15-20% by volume of the friction material,
wherein the friction material contains neither metallic fibers nor copper component, and
wherein the friction material does not contain glass fibers.
US Pat. No. 10,458,031

FE—NI ALLOY METAL FOIL HAVING EXCELLENT HEAT RESILIENCE AND METHOD FOR MANUFACTURING SAME

POSCO, Pohang-si, Gyeong...

1. An Fe—Ni alloy metal foil having excellent heat resilience, manufactured using an EF method and having a thickness of 100 ?m or less (excluding 0 ?m), the Fe—Ni alloy metal foil comprising, by wt %, Ni: 34% to 46%, Fe as a residual component of the Fe—Ni alloy metal foil, and inevitable impurities,wherein microstructure of the Fe—Ni alloy metal foil has a face-centered cubic (FCC) and body-centered cubic (BCC) structure, and an area percentage of BCC is in a range of 5% to 20%,
wherein the Fe—Ni alloy metal foil has a heat resilience rate expressed using Formula 1, below, of 30 ppm or lower,
Heat resilience rate=(L?L0)/L0,  [Formula 1]
where L0 is a length of a metal foil before heat treatment (at a surface temperature of 30° C.), and L is a length of a metal foil after heat treatment and refers to the length of the metal foil when a surface temperature of an alloy having a surface temperature of 30° C. is increased to 300° C. at a rate of 5° C./min, maintained at a surface temperature of 300° C. for 5 minutes, and decreased to 30° C. at a rate of 5° C./min.
US Pat. No. 10,457,776

FORMALDEHYDE FREE CROSSLINKING COMPOSITIONS

ALLNEX NETHERLANDS B.V., ...

1. A reaction product H of at least one cyclic urea U, at least one multifunctional aldehyde A and at least one polyol P,wherein the at least one polyol P is selected from the group consisting of hexanediol, 2-methyl-1,3-propanediol (MP diol), 2-ethyl-1,2-hydroxymethyl-1,3-propanediol, trimethylol propane (TMP), tris (hydroxymethyl) ethane (THME), cyclohexanedimethanol (CHDM), neopentyl glycol (NPG), trimethylpentanediol, dimethylolpropionic acid (DMPA) and pentaerythritol.
US Pat. No. 10,457,777

CARBAMYLATION COMPOSITIONS OF MONOVALENT METAL CONTAINING CATALYSTS, POLYOLS AND UREA COMPOUNDS AND CARBAMYLATION PROCESSES USING THE SAME

Dow Global Technologies L...

1. A carbamylation composition comprising from 0.1 to 1 wt. %, based on total solids, of one or more catalyst (i) which is a monovalent or alkali metal compound containing an anionic group, one or more urea compounds and one or more polymeric polyols, wherein the ratio of moles of the urea compound to molar equivalents of hydroxyl groups in the one or more polyol (urea:OH) ranges from 0.3:1 to 2.5:1 wherein the catalyst (i) is chosen from alkali metal acetylacetonates, 2,2,6,6-tetramethyl-3,5-heptanedionato cesium, alkali metal esters from alkanoic acids, alkali metal esters from sulfonic acids, alkali metal esters from halogenated sulfonic acids, copper (I) sulfonic metal esters, copper (I) halogenated sulfonic acid metal esters, silver (I) sulfonic acid metal esters, silver (I) halogenated sulfonic acid metal esters, cesium trifluoroacetate, and mixtures thereof.
US Pat. No. 10,460,851

SILVER-TELLURIUM-COATED GLASS POWDER, PRODUCTION METHOD FOR SILVER-TELLURIUM-COATED GLASS POWDER, CONDUCTIVE PASTE, AND PRODUCTION METHOD FOR CONDUCTIVE PASTE

DOWA Electronics Material...

1. A silver-tellurium-coated glass powder comprising:a tellurium-based glass powder containing tellurium in an amount of 20% by mass or more; and
a coating layer on a surface of the tellurium-based glass powder, the coating layer containing silver and tellurium as a main component.
US Pat. No. 10,456,498

ANTIMICROBIAL ADHESIVES HAVING IMPROVED PROPERTIES

Avery Dennison Corporatio...

1. An antimicrobial adhesive composition comprising chlorhexidine and a non-gelling disintegrant, which exhibits the following characteristics: (i) after exposure to a temperature of 40° C. and a relative humidity of 75% for a time period of 6 months, the adhesive composition exhibits less than a 20% log reduction in antimicrobial efficacy, based upon an initial antimicrobial efficacy for all of the following microbes: Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA), Candida albicans, and vancomycin-resistant Enterococcus faecium (VRE); and (ii) the composition is free of p-chloroaniline, or if p-chloroaniline is present in the composition, the concentration of p-chloroaniline is less than 1.0% by weight, percentage weight, based upon the initial weight of the chlorhexidine;wherein the non-gelling disintegrant comprises at least one non-gelling disintegrant of microcrystalline cellulose; and
wherein the non-gelling disintegrant is 15% to 45% of the antimicrobial adhesive composition.
US Pat. No. 10,456,499

ADHESIVE ARTICLES FOR MEDICAL APPLICATIONS

3M INNOVATIVE PROPERTIES ...

1. An adhesive article comprising:a siloxane-based pressure sensitive adhesive layer; and
a breathable conformable backing comprising a first surface and a second surface, wherein the siloxane-based pressure sensitive adhesive layer is disposed on the first surface of the breathable conformable backing, and wherein the second surface of the breathable conformable backing comprises a treated surface, wherein the treated surface is not a pressure sensitive adhesive and wherein the treated surface provides increased adhesion to non-siloxane-based pressure sensitive adhesives when compared to the adhesion to the same backing without the treated surface, and wherein the treated surface of the breathable conformable backing is prepared by a coating, and wherein when the surface treatment includes a single coating, the coating covers the entire second surface of the backing and is a low adhesion backsize (LAB) such that in a roll of the adhesive article where the adhesive layer contacts the treated second surface of the backing, the adhesion of the siloxane-based pressure sensitive adhesive to the treated second surface is sufficiently low that the roll may be unwound.
US Pat. No. 10,457,782

POLYMER COMPOSITIONS WITH PBSA PLASTICIZER

Danimer Bioplastics, Inc....

1. A polymeric composition comprising:from about 40 to about 99 weight percent of a first polymer selected from the group consisting of polyvinyl chloride, polylactic acid, and mixtures thereof; and
from about 1 to about 60 weight percent of polybutylene(succinate-co-adipate) (“PBSA”).
US Pat. No. 10,456,500

IMPLANTABLE PREPARATIONS FOR REGENERATION OF TISSUES AND TREATMENT OF WOUNDS, THEIR METHOD OF PREPARATION, AND METHOD OF TREATMENT OF PATIENTS WITH SAID IMPLANTABLE PREPARATIONS

KHORIONYX, La Tour de Sa...

1. A method for preparing a paste containing 14 to 20% per weight of globin and being injectable through a thin 30 g hypodermic needle for regenerating tissues or healing wounds, which can be administered to a patient, consisting of:a) obtaining a whole blood without any anticoagulant agent from a patient,
b) allowing said whole blood sample to clot,
c) separating the obtained serum from said clot,
d) obtaining, from erythrocytes of a blood sample of said patient, after their separation from the plasma or the serum of said sample, an autologous preparation of globin being insoluble at physiological pH, and
e) mixing quantities of said serum and said autologous preparation of globin being insoluble at physiological pH to obtain a paste containing from 14% to 20% per weight of globin and being injectable through a thin 30 g hypodermic needle.
US Pat. No. 10,457,783

ELASTOMER COMPOSITES, BLENDS AND METHODS FOR PREPARING SAME

Cabot Corporation, Bosto...

1. An elastomer composite blend comprising carbonaceous aggregated filler, the carbonaceous aggregated filler having a value of COAN, and natural rubber, the elastomer composite blend, following vulcanization, exhibiting M300/M100 at least (0.017*COAN?0.7) higher than M300/M100 for a vulcanized elastomer composite of the same composition and prepared according to CTV Comparative Method 1, wherein COAN is the oil adsorption number of the compressed filler according to ASTM D3493.
US Pat. No. 10,456,501

COMPOSITIONS AND METHODS FOR CARDIAC THERAPY

Ventrix, Inc., San Diego...

1. A composition comprising digested, decellularized extracellular matrix derived from tissue, the extracellular matrix having a pore size of about 30 to 40 microns, wherein the composition is injectable through a catheter with an inner diameter of 25G or smaller, and wherein the extracellular matrix comprises glycosaminoglycan in a concentration of between about 60 to 120 ?g per mL of the extracellular matrix.
US Pat. No. 10,456,502

BONE VOID FILLER PREPARATION SYSTEM

Fortus Medical, Inc., Mi...

1. A method of recovering connective tissue progenitor cells from bone marrow aspirate comprising:providing a bone void filler preparation container having an inlet port and an outlet port;
placing a bone graft matrix having a particle size of between about 1,000 ?m and 2,000 ?m in the bone void filler preparation container;
depleting a concentration of a red blood cells in a bone marrow aspirate to form red blood cell depleted tissue;
passing the red blood cell depleted tissue through the bone void filler preparation container;
and
retaining the connective tissue progenitor cells in the red blood depleted tissue in the bone void filler preparation container, wherein a selection ratio is a ratio of a connective tissue progenitor cell loading efficiency to a total nucleated cell loading efficiency where the connective tissue progenitor cell loading efficiency is a ratio of the progenitor cells retained in the bone void filler preparation container to the progenitor cells loaded in the bone void filler preparation container and the total nucleated cell loading efficiency is a ratio of a total number of nucleated cells retained in the bone void filler preparation container to the total number of nucleated cells loaded in the bone void filler preparation container where the selection ration is greater than about 3.
US Pat. No. 10,457,785

METHOD OF IMPROVING ADHESION OF CARBON FIBERS WITH A POLYMERIC MATRIX

UT-BATTELLE, LLC, Oak Ri...

1. A method of making a solid composite containing carbon fibers embedded in a polymeric matrix, the method comprising admixing carbon fibers with an unsaturated polymer precursor resin containing carbon-carbon double bonds, and curing the polymer precursor resin to form a cured polymeric matrix that contains said carbon fibers embedded therein, wherein said carbon fibers admixed with the unsaturated polymer precursor resin have covalently bonded on their surfaces a partially cured sizing agent comprised of an epoxy resin, wherein said epoxy resin is covalently attached to a linking group that contains an accessible unsaturated group that reacts with said carbon-carbon double bonds in the unsaturated polymer precursor resin via a vinyl addition reaction, and at least some epoxide groups in the sizing agent are available as uncrosslinked epoxide groups, which corresponds to a curing degree of epoxide groups of no more than about 0.6.
US Pat. No. 10,456,503

POLYMER LAMINATE

Toray University Educatio...

1. A polymer laminate, comprising:2-100 layers each containing a biodegradable resin and having a thickness of 10 nm-400 nm, a thickness of at least one of outermost layers is 10 nm-180 nm, and
a joint portion joining said outermost layers at pinpoints, at a part of an end portion of the laminate, at an entire part of the end portion of the laminate, or combinations thereof,
wherein layers other than the outermost layers may be joined or may not be joined to the outermost layers, and
said at least one of outermost layers contains a polylactic acid-based resin.
US Pat. No. 10,457,786

BIAXIALLY-STRETCHED FILM AND ETHYLENE POLYMER COMPOSITION

PRIME POLYMER CO., LTD., ...

1. A biaxially-stretched film obtained from an ethylene polymer composition (E) comprising an ethylene polymer component (A) fulfilling requirements described below and an ethylene polymer component (B) fulfilling requirements described below,wherein a weight fraction [WA] of the ethylene polymer component (A) is 0.50 or more and 0.87 or less, and a weight fraction [WB] of the ethylene polymer
component (B) is 0.13 or more and 0.50 or less provided that WA and WB total 1.0,
wherein the ethylene polymer component (A) comprises an ethylene polymer (a) and fulfills requirements (A-1) to (A-3) described below:
(A-1) Melt flow rate (MFRA) at 190° C. under a load of 2.16 kg is not less than 0.1 g/10 min and not more than 3 g/10 min;
(A-2) Density (DA) is 907 kg/m3 or more and 940 kg/m3 or less; and
(A-3) Ratio [?]/Mw0.776 of intrinsic viscosity measured in decalin at 135° C. [[?](dl/g)] to weight average molecular weight measured by GPC-viscometry (GPC-VISCO) to the power 0.776 (Mw0.776) is not less than 1.90×10?4 and not more than 2.80×10?4, and
wherein the ethylene polymer component (B) is a copolymer of ethylene and an ?-olefin having 4 to 10 carbon atoms and fulfills requirements (B-1) to (B-5) described below:
(B-1) Melt flow rate (MFRB) at 190° C. under a load of 2.16 kg is not less than 0.01 g/10 min and not more than 30 g/10 min;
(B-2) Density (DB) is 915 kg/m3 or more and 939 kg/m3 or less;
(B-3) Sum of the number of methyl branches [Me(/1000C)] and the number of ethyl branches [Et(/1000C)] per 1000 carbon atoms in 13C-NMR analysis [(Me+Et)(/1000C)] is not more than 1.80;
(B-4) Ratio ?0/Mw6.8 of zero shear viscosity at 200° C. [?0 (P)] to weight average molecular weight measured by GPC-viscometry (GPC-VISCO) to the power 6.8 (Mw6.8) is not less than 0.03×10?30 and not more than 7.5×10?30; and
(B-5) Ratio [?]/Mw0.776 of intrinsic viscosity measured in decalin at 135° C. [[?](dl/g)] to weight average molecular weight measured by GPC-viscometry (GPC-VISCO) to the power 0.776 (Mw0.776) is not less than 0.90×10?4 and not more than 1.65×10?4,
wherein the ethylene polymer (a) is a copolymer of ethylene and an ?-olefin having 4 to 10 carbon atoms and fulfills requirements (a-1) to (a-3) described below:
(a-1) Melt flow rate (MFRa) at 190° C. under a load of 2.16 kg is not less than 0.1 g/10 min and not more than 0.6 g/10 min.;
(a-2) Density (Da) is 890 kg/m3 or more and 928 kg/m3 or less; and
(a-3) (DB?Da)?1 kg/m3,
wherein the ethylene polymer component (A) comprises the ethylene polymer (a) at 40% by weight or more, an ethylene polymer (c) at 20% by weight or more and 40% by weight or less, and an ethylene polymer (d) at 10% by weight or more and 40% by weight or less,
wherein the ethylene polymer (c) is a copolymer of ethylene and an ?-olefin having 4 to 10 carbon atoms and fulfills requirements (c-1) to (c-4) described below, but does not fall within the ethylene polymer (a):
(c-1) Melt flow rate (MFRc) at 190° C. under a load of 2.16 kg is not less than 30 g/10 min and not more than 60 g/10 min;
(c-2) (MFRc?MFRa)?1 g/10 min;
(c-3) Density (Dc) is 910 kg/m3 or more and 940 kg/m3 or less; and
(c-4) (Dc?Da)?1 kg/m3, and
wherein the ethylene polymer (d) is an ethylene homopolymer or a copolymer of ethylene and an ?-olefin having 3 to 10 carbon atoms and fulfills requirements (d-1) and (d-2) described below:
(d-1) Melt flow rate (MFRd) at 190° C. under a load of 2.16 kg is not less than 0.1 g/10 min and not more than 1 g/10 min.; and
(d-2) Density (Dd) is 945 kg/m3 or more and 980 kg/m3 or less.
US Pat. No. 10,457,787

ORIENTED POLYETHYLENE FILMS AND A METHOD FOR MAKING THE SAME

Dow Global Technologies L...

1. A oriented film comprising a polyethylene composition which comprises:from 20 to 50 wt % of a first linear low density polyethylene polymer having a density greater than 0.925 g/cc and melt index (I2) lower than 2 g/10 min, measured according to ASTM D1238, condition 190° C./2.16 kg; and
from 80 to 50 wt % of a second linear low density polyethylene polymer having a density lower than 0.925 g/cc and an I2 greater than 2 g/10 min, measured according to ASTM D1238, condition 190° C./2.16 kg;
wherein the polyethylene composition has an I2 from 0.5 to 10 g/10 min, measured according to ASTM D1238, condition 190° C./2.16 kg, and a density from 0.910 to 0.940 g/cc.
US Pat. No. 10,456,505

BIODEGRADABLE EXTRAVASCULAR STENT

Mallinckrodt Pharma IP Tr...

1. A method for preventing or treating vein graft disease, the method comprising:applying, to a segment or to the whole of a vessel wall of a vein, a dry powder formulation comprising fibrinogen and a fibrinogen activator to prepare an extravascular fibrin polymer stent, wherein the dry powder formulation is applied to an outer surface of the vein, and wherein after 4 weeks, the vessel wall has a thickness less than if the extravascular stent had not been applied to the vein.
US Pat. No. 10,457,788

GAS-BARRIER MULTILAYER FILM

TOYO BOSEKI KABUSHIKI KAI...

1. A gas-barrier multilayer film, wherein(A) a first inorganic thin film layer, (C) a gas-barrier resin composition layer, and (D) a second inorganic thin film layer are stacked in this order with or without intervention of other layers on at least one surface of a plastic film,
the gas-barrier resin composition layer (C) is formed from a gas-barrier resin composition comprising (a) a gas-barrier resin consisting of an ethylene-vinyl alcohol copolymer, (b) an inorganic layered compound, and (c) at least one additive selected from the group consisting of coupling agents and crosslinking agents, and the content of the inorganic layered compound (b) in the gas-barrier resin composition is from 0.1% by mass to 7.0% by mass based on 100% by mass in total of the gas-barrier resin (a), the inorganic layered compound (b), and the additive (c), and
the first inorganic thin film layer (A) and/or the second inorganic thin film layer (D) is a silicon oxide/aluminum oxide two-component inorganic oxide thin film, wherein the content of aluminum oxide is 20% by mass to 75% by mass.
US Pat. No. 10,456,507

TISSUE FUSION AGENT

Aesculap AG, Tuttlingen ...

1. A tissue fusion agent comprising a supporting element and a flock material, wherein the supporting element comprises a material which is meltable under the influence of high-frequency alternating current, heat, ultrasound and/or laser irradiation or is formed from such a material, and wherein the flock material connects directly to a surface of the supporting element with no adhesive layer in between the flock material and the surface of the supporting element.
US Pat. No. 10,458,302

EXHAUST AFTERTREATMENT SYSTEM WITH AMMONIA GAS GENERATOR

Tenneco Automotive Operat...

1. An exhaust aftertreatment system comprising:a reductant tank;
a gaseous ammonia source;
an injector receiving liquid reductant from the reductant tank and gaseous ammonia from the gaseous ammonia source and injecting the liquid reductant into a stream of exhaust gas in a first mode, and injecting the gaseous ammonia into the stream of exhaust gas in a second mode;
a first conduit communicating liquid reductant from the reductant tank to the injector; and
a second conduit communicating gaseous ammonia from the gaseous ammonia source to the injector.
US Pat. No. 10,456,509

CHLORHEXIDINE GLUCONATE COMPOSITIONS, RESIN SYSTEMS AND ARTICLES

3M Innovative Properties ...

1. A composition comprising chlorhexidine gluconate solubilized in a hydrophobic vehicle having a hydrophilic-lipophilic balance of no greater than 10 as determined using the HLB Method,wherein the hydrophobic vehicle comprises two proximate hydrogen-bonding groups,
wherein at least one of the hydrogen-bonding groups is a hydrogen donor,
wherein the composition comprises no greater than 2 parts by weight hydrophilic vehicle per 1 part by weight chlorhexidine gluconate, and
wherein the hydrophobic vehicle is a monoacylglycerol.
US Pat. No. 10,456,766

CONTROLLED RELEASE DUAL WALLED MICROCAPSULES

Encapsys LLC, Appleton, ...

1. Microcapsules whose shell wall comprises at one surface a melamine resin, at its other surface a (meth)acrylate polymer, and between the two surfaces an intermediate region comprising an interpenetrating network and/or copolymer of melamine resin and (meth)acrylate polymer, wherein the melamine resin is derived from an aqueous phase composition comprising melamine resin wall forming materials and the (meth)acrylic polymer is derived from an oil phase composition comprising (meth)acrylate polymer wall forming materials selected from (A) the combination of (a) at least one oil soluble or dispersible amine (meth)acrylate, (b) at least one oil soluble or dispersible acidic (meth)acrylate or at least one oil soluble or dispersible simple acid or both, and (c) at least one oil soluble or dispersible multifunctional (meth)acrylate monomer or oligomer and/or prepolymers of two or more of the foregoing and (B) the combination of (a) at least one oil soluble or dispersible acidic (meth)acrylate, (b) at least one oil soluble or dispersible simple base, and (c) at least one oil soluble or dispersible multifunctional (meth)acrylate monomer or oligomer and/or prepolymers of two or more of the foregoing.
US Pat. No. 10,457,022

SINGLE- OR MULTILAYER FILM COMPRISING BONDED POLYVINYL ALCOHOL

1. A single- or multilayer polymeric film, comprisingat least one (co)polyamide and
one or more water soluble polyvinyl alcohol (s) (PVAs),
wherein said film additionally comprises a bonded polyvinyl alcohol (PVAB), wherein said PVAB
i. is insoluble in water in a range of 18-100° C.,
ii. is soluble in C1 to C3 carboxylic acids,
iii. is capable of reaction with iodine, thereby producing a blue-colored product, and
iv. is capable of reaction with a primary amine, thereby becoming water-soluble,
wherein a ratio CB/CSis at least 0.05, wherein CB is a content of PVAB in said film and CS is a content of PVAS in the film, and
wherein the film is produced by a process comprising
one or more stages including thermal treatment and/or thermal-oxidative treatment of a PVA raw material with participation of elemental oxygen, resulting in at least one pelletized raw polymeric material comprising said PVAS, and
melt (co)extrusion of said film,
wherein said at least one pelletized raw polymeric material used for the melt (co)extrusion comprises at least one of two components, including
a. said PVAB in such concentration that the ratio CB/CS?0.05, and
b. said PVAS comprising
a carbonyl-modified PVA (PVACO), the PVACO being a product of the thermal treatment and/or thermal-oxidative treatment of the PVA raw material, a 4% aqueous solution of said PVACO mixed with an excess of 2,4-dinitrophenylhydrazine having an optical density not less than 0.1 at the wavelength of 490 nm.
US Pat. No. 10,457,794

RUBBER COMPOSITION CONTAINING NATURAL RUBBER AND PROCESS FOR STABILIZING VISCOSITY AND SUPPRESSING ODORS IN NATURAL RUBBER

The Yokohama Rubber Co., ...

1. A method for stabilizing viscosity and suppressing odor in natural rubber, the method comprising:a step of mixing at least a coagulation product of natural rubber latex and an aminoguanidine compound, and
a step of bringing the coagulation product of natural rubber latex and a citric acid aqueous solution into contact prior to the step of mixing the coagulation product of natural rubber latex and an aminoguanidine compound,
wherein the aminoguanidine compound is a bicarbonate or hydrochloride of aminoguanidine.
US Pat. No. 10,457,795

SILOXANE CROSSLINKING PROCESSES EMPLOYING SULFUR COMPOUNDS AND PLATINUM CATALYSTS

MOMENTIVE PERFORMANCE MAT...

1. A process for producing a crosslinked product comprising reacting a mixture constituting (a) an alkenyl silicone, (b) a hydrogen siloxane, (c) a cure inhibitor chosen from an ethylenically unsaturated amide, an aromatically unsaturated amide, an acetylenic compound, an ethylenically unsaturated isocyanate, an olefinic siloxane, an unsaturated hydrocarbon diester, an unsaturated hydrocarbon mono-ester of an unsaturated acid, a conjugated or isolated ene-yne, a hydroperoxide, a ketones, a sulfoxide, an amine, a phosphine, a phosphite, a nitrite, a diaziridine, or a combination of two or more thereof, and (d) a hydrosilylation catalyst, optionally in the presence of a solvent, and (e) a sulfur compound in order to produce the crosslinked product, the sulfur compound (e) being a compound of the formula:R1—S—R2
where (i) R1 and R2 are independently chosen from a H a C1-C20 hydroxyalkyl, a C1-C20 carboxylic acid, or a combination thereof, or (ii) R1 is chosen from a C1-C20 alkyl, and R2 is chosen from a C1-C20 hydroxyalkyl, with the proviso that Formula I is not H2S.
US Pat. No. 10,458,051

FINISHING COMPOSITION FOR PAINTABLE CLOTH AND PRODUCTS OBTAINED

SAINT-GOBAIN ADFORS, Cou...

1. An aqueous finishing composition, comprising:at least one polyglycerol,
at least one organic polycarboxylic acid containing at least three carboxyl groups,
at least one esterification catalyst,
at least one plasticizer, and
at least one thickener selected from a group consisting of cellulose derivatives, succinoglycans and xanthans.
US Pat. No. 10,459,333

HALFTONE PHASE SHIFT PHOTOMASK BLANK AND MAKING METHOD

SHIN-ETSU CHEMICAL CO., L...

1. A method for preparing a halftone phase shift photomask blank having a halftone phase shift film on a transparent substrate, the method comprising the step of depositing a layer containing silicon and nitrogen on the transparent substrate, as a part or the entirety of the halftone phase shift film, by reactive sputtering using a silicon-containing target, an inert gas, and a nitrogen-containing reactive gas, whereinprovided that a hysteresis curve is drawn by applying a power across the target, feeding the reactive gas into a chamber, increasing and then decreasing the flow rate of the reactive gas for thereby sweeping the flow rate of the reactive gas, measuring a sputtering voltage or current value upon sweeping of the flow rate of the reactive gas, and plotting the sputtering voltage or current value versus the flow rate of the reactive gas,
the step of depositing a layer containing silicon and nitrogen includes a transition mode sputtering step of sputtering in a region corresponding to a range from more than the lower limit of reactive gas flow rate providing the hysteresis to less than the upper limit, and in a part or the entirety of the transition mode sputtering step, at least one parameter selected from the power applied across the target, the flow rate of the inert gas, and the flow rate of the reactive gas is increased or decreased continuously or stepwise.
US Pat. No. 10,456,769

METHOD OF CONSTRUCTING SEQUENCING LIBRARY

1. A customized 5184-well plate-based method of constructing a sequencing library in a length ranging from 550 bp to 1000 bp, comprising steps of:1) providing a single-stranded DNA fragment from a biological sample and distributing the single-stranded DNA fragments extracted from 10 to 500 cells into said 5184-well plate such that a probability of homologous chromosome fragments deriving from both mother and father at the same site in their respective genomes presenting in each well is less than 1%;
2) subjecting the single-stranded DNA fragment to whole genomic amplification to obtain a whole genome amplification product;
3) fragmenting the whole genome amplification product using a transposase embedded with two adaptors to obtain a fragmented product with two adaptors respectively at two ends; and
4) amplifying the fragmented product with two adaptors respectively at two ends using a tag sequence and a pair of primers to obtain said sequencing library,
wherein each well of said 5184-well plate has a volume of 350 nL and an effective volume of 200 nL.
US Pat. No. 10,457,796

POLYAMIDE RESIN COMPOSITION AND MOLDED ARTICLE PRODUCED THEREFROM

Lotte Advanced Materials ...

1. A polyamide resin composition comprising:a base resin comprising a polyamide having an intrinsic viscosity (IV) of about 0.9 dL/g or less, and milled glass fibers; and
carbon nanotube flakes having a size of about 1.0 mm to about 5.0 mm, wherein the carbon nanotube flakes are obtained by growing carbon nanotubes on glass fibers, followed by removing the glass fibers,
wherein the polyamide resin composition has a spiral flow length of about 110 mm to about 160 mm, as measured on a specimen obtained by injection molding the polyamide resin composition in a 0.5 mm thick spiral-shaped mold under conditions of a molding temperature of 300° C., a mold temperature of 80° C., an injection pressure of 1,500 kgf/cm2 and an injection speed of 120 mm/s,
wherein the polyamide resin composition has an amount of abrasion dust of about 0.1 mg or less, as measured after a boss and a rib manufactured using the polyamide resin composition are subjected to reciprocating motion at a rate of 50 cycles/min under a load of 2.5 kg for 2 hours, and
wherein a molded article produced from the polyamide resin composition has a surface current discharge time of about 0.1 seconds or less, as measured by a decay time method.
US Pat. No. 10,456,770

HEAVY METAL CAPTURE MASS WITH IMPROVED PERFORMANCES

IFP ENERGIES NOUVELLES, ...

1. A capture mass capable of capturing heavy metals including mercury, contained in a gaseous or liquid feed, said mass comprising:copper which is present at least in part in the sulphide form, CuxSy;
a porous support based on alumina;
said porous support having a total pore volume (TPV) in the range 0.8 to 1.5 cm3/g, a mesopore volume (V6nm-100nm) in the range 0.5 to 1.3 cm3/g, a macropore volume (V100nm) in the range 0.33 to 0.45 cm3/g, and a
ratio between the mesopore volume and the macropore volume (V6nm-100nm/V100nm) of 1 to 1.86.
US Pat. No. 10,457,797

TIRE WITH TREAD WITH OXIDIZED CARBON BLACK

1. A pneumatic tire having a circumferential rubber tread of a rubber composition comprised of, based on parts by weight per 100 parts by weight elastomer (phr):(A) 100 phr of cis 1,4-polyisoprene natural rubber,
(B) about 25 to about 125 phr of reinforcing filler comprised of about 55 to about 100 weight percent rubber reinforcing black comprised of from about 20 to about 100 weight percent surface oxidized carbon black and about 10 to about 50 phr of precipitated silica together with silica coupler having a moiety reactive with hydroxyl groups on said precipitated silica and another different moiety interactive with said diene-based elastomers, and
(C) 1 to 5 phr of tris (2-ethyl hexyl) phosphate.
US Pat. No. 10,457,798

PNEUMATIC TIRE HAVING TREAD WITH HYDROXY-TERMINATED POLYBUTADIENE

1. A pneumatic tire comprising a tread, the tread comprising a rubber composition comprising a diene elastomer, silica, a blocked mercaptosilane, a traction resin, and a low molecular weight polybutadiene functionalized with a hydroxyl functional group.
US Pat. No. 10,456,772

SOLID CARBON DIOXIDE ABSORBENT INCLUDING AMINE OR A COMPOUND THEREOF FOR USE IN THE CAPTURING PROCESS OF DRY CARBON DIOXIDE, AND METHOD FOR MANUFACTURING SAME

Korea Electric Power Corp...

1. A carbon dioxide absorbent manufactured by a method, the method comprising the steps of:(A) preparing a slurry composition including a carrier composition containing a support and an inorganic binder, and a solvent;
(B) preparing solid particles by spray drying the prepared slurry composition;
(C) manufacturing a carrier by dry calcining the solid particles at a temperature between about 350° C. and about 1,000° C. and under an atmosphere of one of air, nitrogen, helium, and a reducing gas, wherein the carrier has a specific surface area of between 50 m2/g and 500 m2/g; and
(D) receiving an amine compound into pores of the manufactured carrier.
US Pat. No. 10,457,799

ETHYLENE-BASED POLYMER COMPOSITIONS FOR IMPROVED EXTRUSION COATINGS

Dow Global Technologies L...

1. A composition comprising at least the following:a) a first composition comprising at least one first ethylene-based polymer, formed by high pressure, free-radical polymerization, and wherein the first composition comprises the following properties: a melt index (I2) from 1.0 to 15.0 g/10 min, and density from 0.910 to 0.940 g/cc;
b) a second composition comprising at least one second ethylene-based polymer, and wherein the second composition comprises the following properties; a melt index (I2) from 1.0 to 1000 g/10 min, and a density greater than 0.940 g/cc;
wherein the melt index (I2) ratio of the melt index (I2) of the second composition to the melt index (I2) of the first composition is from 0.50 to 2.70;
wherein the composition comprises the following properties: melt index (I2) from 2.0 to 20.0 g/10 min, and a density from 0.915 to 0.940 g/cc; and
wherein the first composition is present in an amount from 65 to 95 wt %, based on the weight of the composition.
US Pat. No. 10,459,337

MULTICOLOR PHOTOLITHOGRAPHY MATERIALS AND METHODS

University of Maryland, C...

1. A multicolor photolithography method, comprising the steps of:providing a substrate at least partially coated with a layer of a photoresist composition comprising a reactive monomer and photoinitiator (PI) molecules;
exposing said PI molecules to a first radiation source, thereby exciting said PI molecules from a ground state to a pre-activated state;
exposing said pre-activated state PI molecules to a second radiation source in selected locations, thereby deactivating said pre-activated state PI molecules in said selected locations; and
exposing any of said pre-activated state PI molecules remaining to a third radiation source, thereby exciting said remaining pre-activated state PI molecules to an activated state, and initiating polymerization of said reactive monomer in said photoresist composition.
US Pat. No. 10,457,800

POLYETHYLENE COMPOSITION HAVING HIGH MECHANICAL PROPERTIES AND PROCESSABILITY

Basell Polyolefine GmbH, ...

1. A polyethylene composition comprising:A) from about 30 to about 70 wt. %, based on the total weight of the polyethylene composition, of an ethylene polymer, wherein the ethylene polymer is an ethylene homopolymer or copolymer having a density equal to or greater than about 0.960 g/cm3 and melt flow index MIE at 190° C. with a load of 2.16 kg, according to ISO 1133, of about 50 to 100 g/10 min.;
B) from about 30 to about 70 wt. %, based on the total weight of the polyethylene composition, of a second ethylene polymer, wherein the second ethylene polymer is a copolymer having a MIE value lower than the MIE value of component A),
wherein the polyethylene composition has:
1) a density from about 0.945 to about 0.951 g/cm3, determined according to ISO 1183 at 23° C.;
2) a ratio MIF/MIP from about 25 to about 43, where MIF is the melt flow index at 190° C. with a load of 21.60 kg, and MIP is the melt flow index at 190° C. with a load of 5 kg, both determined according to ISO 1133;
3) a MIF from about 3.5 to less than 8.5 g/10 min.;
4) a HMWcopo index from about 1 to about 40;
5) a long-chain branching index, LCBI, equal to or greater than about 0.83;
wherein the HMWcopo index is determined according to the following formula:
HMWcopo=(110.02×tmaxDSC)/(10 5)
where
(i) ?0.02 is the complex viscosity of a melt in Pa·s, measured at a temperature of 190° C., in a parallel-plate rheometer under dynamic oscillatory shear mode with an applied angular frequency of 0.02 rad/s;
(ii) tmaxDSC is the time in minutes to reach the maximum value of heat flow of crystallization at a temperature of 124° C. under quiescent conditions, measured in isothermal mode in a differential scanning calorimetry apparatus; and
(iii) LCBI is the ratio of the measured mean-square radius of gyration Rg, measured by GPC-MALLS, to the mean-square radius of gyration for a linear PE having the same molecular weight.
US Pat. No. 10,459,338

EXPOSURE ACTIVATED CHEMICALLY AMPLIFIED DIRECTED SELF-ASSEMBLY (DSA) FOR BACK END OF LINE (BEOL) PATTERN CUTTING AND PLUGGING

Intel Corporation, Santa...

3. The structure of claim 1, wherein the block co-polymer structure is disposed above a pattern of alternating metal lines and dielectric lines disposed above the substrate.
US Pat. No. 10,456,775

METHOD OF PREPARING ZINC FERRITE CATALYST

LG CHEM, LTD., Seoul (KR...

1. A method of preparing a zinc ferrite catalyst, the method comprising:a) dissolving a zinc precursor and an iron (III) precursor in water to prepare an aqueous metal precursor solution;
b) precipitating a solid catalyst precursor by vaporizing the water in the aqueous metal precursor solution, wherein the vaporizing is carried out at 60 to 80° C. for 2 to 4 hours using an evaporator; and
c) firing the precipitated solid catalyst precursor at a temperature from 850° C. to 1000° C. to prepare the zinc ferrite catalyst.